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I present two computational studies of gene regulation: the first is a machine learning 
approach to predict potent shRNAs to knock down specific endogenous mRNAs; the 
second is an in-depth analysis of the relationship between chromatin accessibility and 
the functional state of tumor-specific CD8+ T cells.  
Short-hairpin RNA, or shRNA, are synthetic RNA molecules that can be used to 
silence mRNA transcripts in a sequence-dependent manner and are used extensively in 
gain- and loss-of-function genetic studies. In order to predict which shRNA molecules 
will be potent despite changes in underlying shRNA technology, we developed a 
cascaded support vector machine, SplashRNA, trained on both types of shRNA 
backbone, miR-30 and miR-E. This strategy allows us to learn basic shRNA potency 
rules on our larger but older miR-30 dataset and followed by more precise miR-E-
specific rules on our smaller miR-E training set. We demonstrate that SplashRNA 
outperforms all other shRNA prediction methods while limiting off-target effects 
through careful curation of mRNA transcript data and we have developed an open-
source implementation of this algorithm available at splashrna.mskcc.org. 
 Tumor-specific T cells have been found in patients’ tumors, but these tumors 
continue to progress, indicating that these T cells are not functional. A subset of patients 
in this situation have responded to checkpoint blockade therapy, which can rescue 
silenced T cells, but not all patients are responsive to this treatment and some only 
 
 
 
respond for a brief period. Here, we investigate the chromatin accessibility landscape of 
normal and dysfunctional tumor-specific T cells in order to determine the regulatory 
changes that take place when T cells are in a dysfunction-inducing tumor environment. 
We computationally identify and pharmacologically validate NFAT and TCF family 
members as critical in this differentiation to dysfunction. We also identify cell surface 
markers that differentiate between reprogrammable and fixed cells, a strategy that may 
be used to determine if patients are candidates for checkpoint blockade therapy.
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CHAPTER 1 	
INTRODUCTION 
 
1.1 Introduction to gene regulation 
 
Although humans1 and mice2 have about the same number of protein-coding genes as 
the relatively simple nematode Caenorhabditis elegans (~ 20,000 genes3), and about 
four times as many genes as budding yeast Saccharomyces cerevisiae (~6,000 genes4), 
the regulation of those genes are orders of magnitude more complex5. Completing the 
sequence of the first human genome in the early 2000s ushered in a new age of 
biological research. It was discovered that although some diseases are caused by single 
mutations in coding regions that are relatively easy to identify, many more cannot be 
explained by a single mutation and are caused by disruptions in complex gene 
regulatory networks or inappropriate responses to environmental cues. As genomic and 
transcriptomic regulation are highly relevant in the clinic and for our understanding of 
biology, questions of gene regulation have been approached from many angles 
including chromatin organization, epigenetic signatures, alternative mRNA splicing, 
alternative 5` and 3` untranslated regions, intron retention, and more. 
 In this work, I describe two studies that attempt to address different questions in 
gene regulation. The first is a machine learning approach, SplashRNA, designed to 
predict potent short-hairpin RNAs to knock down endogenous mRNA transcripts in a 
sequence specific manner. The second is an epigenetic and transcriptomic profiling of 
tumor-specific CD8+ T cells (TSTs) to determine the mechanisms of dysregulation in 
TSTs relative to normal cytotoxic T-cells. 
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1.2 Introduction to shRNA technology 
 
1.2.1 History of RNA interference 
 
Focused and large-scale functional genomics approaches performed in mammalian cells 
and model organisms have the potential to uncover gene interaction networks for the 
better understanding of homeostasis and disease, and the development of novel 
therapeutics. For over a decade, RNA interference (RNAi) has been the technology of 
choice for both positive and negative selection screens in higher eukaryotes and has 
provided unparalleled insight into gene function. 
 RNAi provides a programmable mechanism for reversible suppression of gene 
expression6. Through a highly conserved pathway, the RNAi machinery processes 
double-stranded RNAs into small RNAs that guide the repression of complementary 
genes [reviewed in 7]. Experimental RNAi acts by providing exogenous sources of 
double-stranded RNA that mimic endogenous triggers to enable rapid gene knockdown. 
Importantly, the single component nature of RNAi tools makes them extremely 
amenable to large-scale applications and delivery in nearly any model system. RNAi 
triggers can be designed to either inhibit specific messenger RNAs (mRNAs) or 
suppress all splice isoforms through targeting of the common transcript.  
 However, perfect sequence complementarity is neither necessary nor sufficient 
for strong RNAi knockdown8. shRNA may bind to off-target sites with few mismatches 
and may not bind sites even if there is a perfect sequence match. There are also 
sequence restrictions of the endogenous miRNA processing machinery such that some 
sequences are more efficiently processed than others. Because not all the sequence 
restraints for shRNA and other RNAi technologies have been elucidated, there is still a 
relatively low rate of success of shRNAs. Usually only about 50% of predicted shRNAs 
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are potent using existing prediction tools, leading to a significant amount of lost time 
and resources9. 
 
1.2.2 A Sensor assay to test potency of large shRNA libraries 
 
To better understand the sequence requirements for potent RNAi and identify efficient 
microRNA-embedded shRNAs for any gene, we have developed a functional high-
throughput “Sensor” assay that allows biological assessment of ten thousands of 
shRNAs in parallel10. This assay relies on a “Sensor” construct where the expression of 
the shRNA is driven by a Tet-inducible promotor. Also a part of this construct is the 
Venus gene, which codes for a yellow-fluorescent protein (YFP), under a constitutively 
active promoter. The cognate sequence of the shRNA is included in the 3`UTR of the 
Venus sequence and acts as a target for the shRNA. If the shRNA is potent and 
expressed, it will bind to this target sequence and the Venus RNA will be targeted for 
degradation, decreasing the amount of fluorescence detected. Thus, a pool of cells 
containing a library of shRNAs can be sorted using fluorescence activated cell sorting 
Figure 1.1: shRNA sensor construct.  
The target Sensor sequence harbors the reverse-complement of the Tet-inducible 
shRNA and is located in the 3’UTR of the constitutively active Venus reporter. Venus 
expression then directly reports shRNA potency. Figure is adapted from Figure 1a of 
Fellmann et al, Mol Cell, 2011.  
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(FACS) by their repression of Venus (Figure 1.1, adapted from 10). Multiple rounds of 
sorting on- and off-doxycycline leads to a purified population of cells containing 
constructs with potent shRNA. The constructs of these cells are then sequenced to 
determine the shRNA identities.  
 We initially applied this Sensor assay to evaluate 20,000 shRNAs at each step of 
microRNA biogenesis. To design these sequences, we completely tiled nine genes. This 
allowed us to uncover in an unbiased manner both known and novel processing step-
specific features of potent RNAi. We also used this reporter assay to generate focused 
and genome-wide shRNA libraries11,12, biologically testing well over 300,000 
microRNA-embedded shRNAs overall. While the Sensor assay robustly identified the 
most potent sequences, generating large-scale libraries using this approach was time 
consuming and impractical as it became a balance between reducing the number of 
genes in a library versus reducing the number of candidate shRNAs per gene to be 
tested. Yet, the Sensor assay generated invaluable datasets that when integrated 
correctly can serve as ideal training and validation sets for computational shRNA 
prediction algorithms.  
 
1.2.3 shRNA backbones 
 
The backbone of an shRNA is the construct into which the targeting shRNA sequence is 
placed. As an shRNA is processed by the cell’s miRNA production pathway, the 
backbone must be similar enough to endogenous sequences to be recognized. For this 
reason, a commonly used shRNA backbone was based upon the human MIR30A 
sequence.  
To increase the potency of all shRNAs, especially when expressed from a single-copy 
genomic integration, we have established an optimized microRNA backbone (miR-E) 
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that boosts processing efficiency 10-30 fold when compared to the standard miR-30 
backbone, leading to much stronger target knockdown in most cases13. The miR-E 
scaffold restores a conserved 5’-DCNNC-3’ motif in the 3’-flank of the backbone that is 
recognized by components of the microprocessor complex for efficient biogenesis, 
similar to most endogenous microRNAs13,14. This conserved sequence had been 
replaced with an EcoRI restriction site in the miR-30 backbone, leading to decreased 
shRNA processing efficiency. Although this change increased the overall efficiency of 
shRNAs, it increased the difficulty of potent shRNA prediction as the miR-E reagents 
behaved slightly differently than their miR-30 predecessors. 
 
1.2.4 Existing methods of shRNA prediction 
 
Algorithmic developments and prediction performance are closely tied to the quality, 
size and implementation of the (siRNA or shRNA) datasets used for training. While 
initial rules of RNAi potency contained many non-sequence features derived from 
relatively low-throughput studies15-17, later rules inferred from larger screens found that 
sequence based features are more predictive18,19 and indirectly capture the other 
characteristics20. As one of the larger early studies, the BIOPREDsi algorithm, a non-
linear neural network, was trained on over 2,000 functionally tested siRNAs targeting 
34 genes and set a new performance standard. Using the same dataset, the DSIR 
algorithm improved performance through the use of an L1 regularized linear model with 
a combination of a degree 3 spectrum-kernel and sequence and position features19,21. 
However, it soon became apparent that the rules governing shRNA efficiency differ 
from the ones dictating siRNA potency10,22, explaining why siRNA based algorithms 
performed relatively poorly in shRNA prediction tasks. This difference is likely due to 
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the additional processing requirements imposed on stem-loop shRNAs by the Dicer 
complex, and on microRNA-embedded shRNAs by the Drosha and Dicer complexes. 
 Thus, we and others have previously used our large-scale microRNA-based 
shRNA potency datasets to generate miR-30 specific prediction algorithms12,23. 
However, with a shift towards the use of the much more efficiently processed miR-E 
backbone13, these algorithms are no longer accurately trained for the task at hand as key 
sequence requirements have changed. In chapter 2, I describe the development of 
SplashRNA, a cascaded support vector machine classifier for predicting potent miR-E 
based shRNA that outperforms all existing prediction methods. 
 
1.3 T cell introduction 
 
1.3.1 Introduction to CD8+ T cell function 
 
Although there are many cell types involved in the immune system and immune 
response, here we will focus on CD8+ or cytotoxic T cells. These cells are able to kill 
invading pathogens when activated by a major histocompatibility complex (MHC) 
protein presenting their specific antigen (reviewed in 24). During an infection with a 
bacteria or virus, antigen-naive T cells will be activated by an antigen-presenting cell 
presenting their specific antigen, often a component of the invading pathogen. Activated 
T cells differentiate into effector cells, undergo clonal expansion, and search for their 
specific antigen. When infected target cells presenting this antigen are located, the 
effector T cells bind to the target cell’s surface and release cytotoxins, triggering 
apoptosis. 
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1.3.2 Tumor-specific T cells and checkpoint blockade therapy 
 
Cytotoxic T cells are also able to play a role protecting the body by killing cancerous 
cells. During cancer’s progression, even during pre-malignant stages, both cancer-
inducing “driver” mutations and benign “passenger” mutations frequently occur25. If 
these mutations occur within the coding sequence of a gene, the protein product may 
have an altered polypeptide sequence as a result. As part of the major histocompatibility 
complex (MHC) class I antigen presentation pathway, cytosolic proteins are degraded 
and portions of these proteins, called polypeptides, are presented on the cell surface as 
part of a MHC-peptide complex. Polypeptides containing a cancer-induced alteration 
may be presented through this pathway and as these molecules are not endogenous, T 
cells with antigens specific to these polypeptides will not have been eliminated by 
central or peripheral self-tolerance mechanisms26. Therefore, it is possible for a T cell to 
recognize and bind the altered polypeptide and target the presenting cell for destruction 
(Figure 1.2, adapted from 26).  
Cancer cells may avoid this type of immune targeting by both creating an 
immunosuppressive microenvironment and direct suppression of T cell activity27. This 
suppression is achieved by aberrantly expressing ligands for immune checkpoint 
molecules, the most well-studied of which are CTLA-4 (cytotoxic T-lymphocyte 
antigen 4) and PD-1 (programmed death 1). These molecules are expressed in normal 
cells to prevent autoimmunity. Several biologic therapies have been developed to target 
and inhibit these and other immune checkpoint molecules, a strategy termed checkpoint 
blockade (reviewed in 28). Some of these drugs are monoclonal antibodies that bind to 
CTLA-4 (ipilimumab, the first approved checkpoint blockade drug) or PD-1 
(Nivolumab and Pembrolizumab) and interrupt the interaction between these receptors 
and their ligands. Blocking these interactions leads to increased T cell activity and has 
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been shown to be effective in patients with advanced and metastatic cancers including 
lung cancer and melanoma. 
 These checkpoint blockade molecules have not been a panacea, however. As 
they activate immune cells globally, many patients treated with these drugs develop 
autoimmune reactions such as colitis or hepatitis28. More troubling however, is that not 
all patients with cancers expressing PD-L1 and CTLA-4 ligands respond to these 
treatments. Developing methods to determine which patients will respond to immune 
checkpoint blockade therapy and how to induce a therapeutic response in the remaining 
population are research areas of critical importance in oncology research and will be 
addressed in this work.  
 Even when immune checkpoint mechanisms have been blocked, T cells do not 
always activate and attack their target cancer cells. Additionally, many patients 
experience resistance to this therapy after a relatively short period of time.28 This 
persistent T cell dysfunction is similar to the T cell exhaustion observed in chronic viral 
infection. T cells in both the tumor environment and in chronic viral infection have 
Figure 1.2: Polypeptides presented on cell surface by MHC class I pathway.  
Mutations in tumor cells (red, bottom) may lead to altered polypeptides being 
presented. As these are non-native polypeptides, CD8+ T cells may recognize and 
bind these presented tumor neoantigens. (Figure adapted from Fritsch, Hacohen & 
Wu, OncoImmunology 2014) 
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decreased effector function and express inhibitory molecules such as PD-1, LAG-3, 
TIM-3, and CTLA-4 and have an altered transcriptional state relative to normal effector 
T cells in response to persistence of their specific antigen29. One hypothesis is that this 
altered phenotypic and expression state is accompanied and perhaps driven by a 
correspondingly altered epigenetic state. In chapter 3, we investigate how the epigenetic 
state in tumor-specific T cells is altered even in pre-malignant lesions, before the tumor 
microenvironment is established and how this correlates with reprogrammability of 
tumor-specific T cells. 
 
1.3.3 A mouse model of tumor-specific dysfunctional CD8+ T cells 
 
In order to study the progression of dysfunction in tumor-specific CD8+ T cells (TST), 
we used a tamoxifen-inducible, autochthonous liver cancer model (AST-Cre-ERT2) in 
which the SV40 large T antigen (TAG) acts as both the tumor-initiating factor and the 
tumor-specific antigen30. The AST cassette consists of three components: the 
hepatocyte-specific albumin promoter, a loxP flanked stop-cassette, and the SV40 large 
T antigen (Figure 1.3). Under normal conditions, mice with this construct will not 
express the T antigen due to the presence of the stop cassette. When Cre is added to the 
system or expressed endogenously, the stop-cassette between the loxP sites is deleted 
and the T antigen is expressed. Mice with the AST construct under a liver-specific 
promoter are crossed with mice containing a tamoxifen-inducible Cre gene, allowing 
the deletion of the stop-cassette and expression of the SV40 large T antigen to be 
controlled through administration of tamoxifen in the offspring. This experimental 
scheme allows for studies in early tumor development and differentiation along with 
studies of TAG-specific T cell (TCRTAG) efficacy in early tumorigenesis, as the exact 
day of tumor initiation is known.  
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 To accompany this study of TSTs, we also transferred congenically marked 
naive (N; CD44loCD62Lhi) TCRTAG cells into wild-type C57BL/6 mice. These wild-
type mice were then immunized one day later with a recombinant Listeria 
monocytogenes strain expressing this same TAG epitope (LmTAG)7,14. This lead to a 
normal immune response in which the naive TCRTAG cells recognized and bound to the 
TAG epitope, activated and differentiated to effector cells, and then further 
differentiated to memory cells once the LmTAG infection was cleared. This is a 
controlled system for studying the progression of T cells in a normal environment. 
 As shown in Figure 1.4, T cells were extracted from both the normal model and 
the tumor model at various time points. We then performed both RNA-seq and ATAC-
seq on these cells to profile them transcriptionally and epigenetically.   
 
 
 
 
Figure 1.3: Tamoxifen-inducible liver cancer model.  
Tam-induced Cre-mediated excision of the flox-stop cassette leads to SV40 large 
T antigen expression.  
Alb-P/E “Stop”-cassette SV40 Tag 
loxP loxP 
Cre-recombinase 
Tumor initiation in the liver 
Alb-P/E SV40 Tag 
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1.3.4 Chromatin profiling to determine functional state of CD8+ T cells  
 
 As every cell contains the complete genetic code of the organism, spanning 
about 3 billion bases in humans and mouse1,2, DNA is, by necessity, tightly compacted. 
The organization of DNA folding is tightly regulated and this regulation partially 
determines the genetic programs activated. Regions of DNA that are folded less tightly 
are accessible to DNA binding proteins including RNA polymerase and transcription 
factors which regulate gene transcription both proximally and distally31. 
 ATAC-seq (Assay for Transposase Accessible Chromatin followed by 
sequencing)32 is a genome-wide high-throughput sequencing method for detecting 
regions of open chromatin, similar to DNase-seq. However, ATAC-seq can be 
performed with many fewer cells than DNase-seq allowing for profiling of less-
common cell populations. The critical step of ATAC-seq is the addition of a transposase 
(Tn5) loaded with sequencing adapters to the cells of interest. In less tightly compacted 
regions of DNA where the Tn5 transposase is able to bind, it will cleave the DNA and 
insert its adapters into the genome. This combines the genome fragmentation and 
tagging steps of a standard sequencing library preparation protocol into a single 
Figure 1.4: Experimental design. 
Experimental design in both the acute infection model (a) and during tumorigenesis 
(b). Days indicate time points at which TCRTAG cells were isolated and analyzed. 
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“tagmentation” step. These fragments of DNA are then purified, sequenced, and 
mapped back to the genome to determine which regions were accessible at the time 
when the transposase was added (Figure 1.5, adapted from Figure 1a of 32).  
 
 Paired-end ATAC-seq sequencing libraries have a distinctive insert size 
distribution due to two factors: the 10.5bp helical pitch of B-DNA, the most common 
helical structure of DNA, and the spanning of DNA across nucleosomes. DNA that is 
wrapped around a nucleosome protected from cleavage by the transposase, leading to an 
enrichment of reads with lengths that are multiples of about 146-147 bases, the length 
of DNA protected by the nucleosome (Figure 1.6)33. Checking for the presence of these 
two markers is one quality control step in the ATAC-seq library preparation. 
Figure 1.5: Schematic of ATAC-seq procedure.  
Tn5 transposase loaded with sequencing adapters (red, blue) is added to chromatin. 
In regions where the transposase is able to bind, the adapters are inserted and DNA 
is cleaved. The resulting fragments are purified, amplified, and sequenced. (Figure 
adapted from Buenrostro et al, Nat Methods 2013)  
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 In addition to and perhaps more important than knowledge of nucleosome 
positioning, regions of open chromatin indicate potential sites of transcription factor 
binding and regulation. It is not feasible to experimentally test for all DNA binding 
protein occupancies, but we can infer the binding of these proteins using sequence 
motifs. By comparing the known binding motifs of transcription factors to the sequence 
under the summit of reproducible peaks, the probability that a transcription factor is 
bound to a peak region can be estimated. By comparing genome-wide changes in 
transcription factor binding and occupancy, global changes in transcription factor 
activity can be inferred. This analysis is performed in chapter 3 to compare transcription 
factor activities in normal and dysfunctional CD8+ T cells. 
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Figure 1.6: Representative ATAC-seq library insert-size distribution.   
Tag count enrichments at multiples of 178bp represent nucleosome-protected tags. 
Smaller peaks occuring every 10.5bp indicate the 10.5bp helical pitch of DNA. 
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CHAPTER 2  
PREDICTION OF POTENT shRNA WITH A SEQUENTIAL 
CLASSIFICATION ALGORITHM 
Portions of this chapter first appeared in Fairchild* et. al.9 and were written in 
collaboration with Raphael Pelossof, Christof Fellmann, and Christina Leslie. 
 
2.1 Introduction 
 
Experimental RNA interference (RNAi) acts by providing exogenous sources of 
double-stranded RNA that mimic endogenous triggers and enable reversible, transcript-
specific gene knockdown7. Whereas short interfering RNAs (siRNAs) allow for rapid 
gene knockdown, they are not suitable for many long-term and in vivo studies due to 
their transient nature. Stem-loop shRNAs can be used as a continuous source of RNAi 
triggers when expressed from suitable vectors, but suffer from various technical 
limitations including inaccurate processing34 and off-target effects through saturation of 
the endogenous microRNA machinery35-37. State-of-the-art microRNA-based shRNA 
vectors can overcome these limitations by providing a natural substrate of the RNAi 
pathway that is accurately and efficiently processed13,38-40 resulting in minimal or no 
off-target effects when expressed from a single genomic integration (single-copy)10. 
 Still, our limited understanding of RNAi processing requirements and the lack of 
robust algorithms for the design of microRNA-based shRNAs with high potency and 
low off-target activity has hampered the utility of RNAi tools.To understand the 
sequence requirements of potent RNAi and identify efficient microRNA-based shRNAs 
for any gene, we previously developed a functional high-throughput “Sensor” assay that 
enables biological assessment of tens of thousands of shRNAs in parallel (Figure 
2.1a)10. We used this assay to generate focused and genome-wide shRNA libraries11,12. 
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Furthermore, to increase the potency of all shRNAs, especially when expressed at 
single-copy, we established miR-E, an optimized microRNA backbone that boosts 
processing efficiency13,14 and leads to stronger target knockdown when compared to 
standard miR-30 designs13.  
Figure 2.1: Computational modeling of advancements in shRNA technology.  
(a) Schematic of our previously published Sensor assay that enables large-scale 
functional assessment of shRNA potency. (b) Schematic of diverse biological 
shRNA potency datasets and their feature (top) and class label (bottom) 
distribution biases. Unbiased large-scale sets include a comprehensive 
representation of negatives but contain few potent shRNAs (left panel, 
potent=yellow). Sets selected using prediction tools show a higher rate of 
positives, at the cost of changing the feature distribution of the negatives (middle 
panel). Use of the optimized miR-E backbone changes the requirements for potent 
RNAi, altering the target prediction rule (right panel). (c) Concept and equation of 
SplashRNA. We model the advancement in shRNA technology as a sequential 
support vector machine (SVM) classifier. The first classifier is trained on miR-30 
data and removes non-functional sequences and the second classifier is trained on 
miR-E data to increase prediction performance of the remaining shRNAs in the 
miR-E setting. The final output is a weighted combination of the scores from both 
classifiers. 
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The performance of shRNA prediction tools depends on the quality, size and design of 
the datasets used for training. While initial rules of RNAi potency contained many non-
sequence elements15-17, later rules inferred from larger screens found that sequence 
based features are more predictive18,19 and capture the other characteristics20. 
BIOPREDsi, a neural network approach, was trained on over 2,000 functionally tested 
siRNAs and set a new performance standard18. Using the same training dataset, DSIR 
improved prediction through the use of an L1 regularized linear model with a 
combination of position-specific nucleotide features and mono-, di-, and tri-nucleotide 
counts19,21. However, the rules governing siRNA potency differ from the ones dictating 
shRNA potency due to the additional biogenesis steps10,22, and siRNA-based algorithms 
perform relatively poorly in shRNA prediction tasks. Hence, we and others have 
previously used our large-scale shRNA datasets to generate miR-30 specific prediction 
algorithms12,23. Still, with a shift towards the more efficiently processed miR-E 
backbone, these algorithms are no longer designed for the task at hand as key sequence 
requirements have changed.  
 
2.2 A sequential classifier to exploit diverse RNAi datasets 
 
To build an accurate miR-E shRNA predictor, we developed SplashRNA, a sequential 
learning algorithm combining two support vector machine (SVM) classifiers trained on 
judiciously integrated data sets (Table 2.1). SplashRNA models the sequential advances 
in shRNA technology to enable efficient learning on unbiased and biased data (Figure 
2.1b,c). To train the algorithm, we generated a large-scale miR-30 data set (referred to 
as M1); and a miR-E data set (referred to as miR-E) using our RNAi Sensor and 
reporter assays, respectively 10,13. We also incorporated the previously published TILE10 
and UltramiR12 sets. The UltramiR dataset uses shRNAs constructed using the UltramiR 
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backbone. This backbone has been shown to be functionally indistinguishable from the 
miR-E backbone12. 
 
 
Table 2.1: shRNA potency datasets used for training and performance assessment 
The total count of shRNAs in each library is indicated (N) along with the number of 
positive (N-pos) and negative (N-neg) examples 
 
 Backbone Screen type N N-pos N-neg Use 
TILE miR-30 Sensor assay, 
pooled 
18720 5736 12685 Training, 
validation 
M1 miR-30 Sensor assay, 
pooled 
20324 9602 10722 Training, 
validation 
mRas + hRAS miR-30 Sensor assay, 
pooled 
9804 1139 8665 Validation 
shERWOOD 
250k 
miR-30 Sensor assay, 
pooled 
227673 53234 174439 Validation 
miR-E miR-E Reporter assay, 
one-by-one 
397 170 227 Training, 
validation 
UltramiR UltramiR* Cell viability, 
pooled 
780 378 402 Training, 
validation 
Essential genes, 
Top50 hits 
Mini miR-
30 with 
DCNNC 
motif* 
Cell viability, 
pooled 
1002    
Validation 
Sensitivity 
genes, Top20 
hits 
Mini miR-
30 with 
DCNNC 
motif* 
Toxin resistance 
and sensitivity, 
pooled 
500   
Validation 
* These miRNA-based shRNA backbones are functionally equivalent to miR-E. 
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The TILE dataset is unbiased as it was generated by completely tiling nine genes. 
However, this design strategy produces a low fraction of potent shRNAs. To reduce 
costs and increase the ratio of potent shRNAs tested, subsequent screens only assessed 
shRNAs predicted to be efficient by various in silico methods11,12. The M1, miR-E, and 
UltramiR datasets are based on preselected input libraries showing biased coverage of 
the sequence space and divergence in the nucleotide composition of potent shRNAs 
relative to the TILE dataset (Figure 2.2). When combined with the unbiased TILE set, 
these datasets comprehensively sample the distributions of features of non-functional 
and functional shRNAs. Effective integration of all sets is thus crucial for efficient miR-
E shRNA prediction. 
Figure 2.2: Nucleotide representation of positive (potent) shRNAs from the 
indicated datasets.  
Shown are the nucleotides one to eight of the guide strand (starting in the center), 
including the entire seed region. Unbiased TILE (miR-30) set, showing a diverse 
nucleotide composition (left panel). Preselected M1 (miR-30, selected by DSIR + 
sequence rules derived from sensor assay) set, showing a biased nucleotide 
representation (middle panel). Preselected miR-E + UltramiR set, showing a different 
nucleotide distribution due to the altered shRNA backbone. More shRNAs starting 
with a C were found to be potent in this set relative to TILE (p-value = 0.002, Fisher’s 
exact test), indicating less restrictive sequence requirements when using the miR-E 
backbone. 
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Combining diverse data sets presents a machine-learning challenge. Our approach of 
using a sequential classifier stems from classification strategies used in face 
detection41,42, where a first classifier evaluates simple face-like features to reject 
obvious non-faces and a second classifier evaluates refined features on retained 
 Figure 2.3: Kernel selection.  
(a) Schematic of the first support vector machine (SVM) classifier that serves to 
eliminate non-functional sequences and prioritize shRNAs that are likely to be 
potent. (b) Schematic of the kernel representation used by SplashRNA. A 
weighted degree kernel is calculated across the entire guide sequence, while two 
spectrum kernels are calculated across nucleotides 1-15 and 16-22, respectively. 
(c) Testing of multiple kernel combinations in a leave-one-gene-out nested cross-
validation setting on the TILE. All_kernels: wdk + spec1 + spec2. Spec1: spectrum 
kernel over positions 1-15. Spec2: spectrum kernel over positions 16-22. 
Spec1_spec2: spec1 + spec2. Wdk: weighted degree kernel over positions 1-22. 
Wdk_spec1: wdk + spec1. Wdk_spec2: wdk + spec2. 
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potential faces. Similarly, SplashRNA contains a sequence of two SVM classifiers  
trained on miR-30 and miR-E data. The miR-30 classifier evaluates shRNA sequence 
features to reject obvious non-functional shRNAs, whereas the miR-E classifier 
evaluates refined sequence features for retained, potentially potent shRNAs (Figure 
2.1c). Each classifier is composed of a combination of k-mer feature 
representations43,44. To capture AU content and position-specific k-mer features10, we 
represented an shRNA as a sum of a spectrum kernel on sequence positions 1–15, a 
spectrum kernel on sequence positions 16–22 and a weighted degree kernel on the 
entire sequence (Figure 2.3b). We found that this kernel combination yields the best 
performance (Figure 2.3c).  
Initially, we trained the miR-30 classifier on the combined positives and 
negatives from the TILE and M1 sets (Table 2.1). This yielded a classifier that scored 
well in validation tests but was outperformed by one trained on TILE alone (Figure 
Figure 2.4: Incorporation of M1 dataset to generate a miR-30 classifier.  
(a) M1 potency score distribution. Cutoffs (green lines) were calculated by fitting 
Gaussian distributions to the modes and setting thresholds at 5% FPR and 5% FNR. 
(b) Incorporation of M1 positives, negatives or both into the TILE training set was 
tested in a nested leave-one-gene-out cross-validation setting. Inclusion of M1 
negatives deteriorated performance on the TILE dataset, whereas inclusion of the 
M1 positives alone improved performance. Note: TILE+M1pos = SplashmiR-30, the 
miR-30 classifier. (c) Incorporation of M1 positives into the TILE training set 
improved performance on the external shERWOOD miR-30 dataset.  
 
 
 
21 
2.4b). We found that due to the biased selection strategy used to design the M1 screen, 
the potency of the negative shRNAs in the M1 screen were still more potent than the 
negative shRNAs from the TILE screen. Therefore, combining the M1 negatives with 
the TILE negatives degraded the performance of the model as they lowered the relative 
importance of the unbiased TILE negatives. Consequently, our best miR-30 classifier 
(SplashmiR-30) was obtained by training on a combined data set of TILE and M1 
positives only (Figure 2.4b,c). The miR-E classifier (SplashmiR-E) was trained on the 
combined miR-E and UltramiR data sets using the same kernel combination. For the 
final SplashRNA predictor, SplashmiR-30 and SplashmiR-E were combined by tuning two 
hyperparameters: theta (θ, a threshold above which predictions are passed to the second 
classifier) and alpha (α, the relative weighting of the scores from the two classifiers for 
predictions evaluated by the second classifier; Figure 2.1c, Equation 2.1). By 
calculating the precision-recall trade-off between the two classifiers, we chose values 
for theta and alpha that maintained the high performance of the first classifier while also 
predicting well on miR-E data (Figure 2.5a-c). Note that the performance of a 
sequential classifier equals or exceeds that of a linear combination since one can set the 
threshold to a large enough value such that all examples are evaluated by both 
classifiers (Figure 2.5a).  
 
2.3 Training the component SplashRNA classifiers 
 
When fitting the regularization parameter C for our miR-30 SVM, we used leave-one- 
gene-out nested cross-validation. We grouped shRNAs from the TILE miR-30 data set 
by target gene into outer-folds. Then for each outer fold, we held out shRNAs targeting 
one gene and optimized the parameter C on the shRNAs targeting the remaining genes 
through ten-fold cross-validation. The M1 positive set was added to all training sets but 
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was not used for selection of C or for validation. Performance on the TILE set is 
reported on the outer held-out genes (Figure 2.4b). We trained our final classifier with 
the parameter setting C = 15 using all the TILE and M1 positive shRNAs. This 
classifier was used to predict on all other data sets. 
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Figure 2.5: Calibration of the sequential SVM classifier SplashRNA.  
(a) Precision-recall trade-off between the two classifiers SplashmiR-30 and 
SplashmiR-E. Selection of alpha and theta hyperparameters leads to varied 
performance (area under the precision-recall curve, auPR) on the TILE miR-30 (x-
axis) and miR-E + UltramiR (y-axis) sets. Each line represents a setting of alpha; 
points on the line represent distinct theta values. The circle indicates the alpha and 
theta choices for the final sequential classifier (SplashRNA, alpha = 0.6, theta = 
1.1). Dotted line: performance of the convex linear classifier without a threshold at 
every alpha. (b) Performance on the TILE set, varying the value for theta with 
alpha set to 0.6. The insert shows the first 15% of the precision-recall.  (c) 
Performance on the miR-E + UltramiR set, varying the value for theta with alpha 
set to 0.6.   
 
 
 
 
24 
 Similar to the training regimen for the miR-30 SVM, we used nested ten-fold 
cross-validation to fit the C parameter for our miR-E SVM. We did not use a leave-one-
gene-out strategy however due to the lower number of shRNAs targeting each gene. 
Instead, the miR-E and UltramiR sets were combined and split into ten outer folds. 
Within each of these folds, ten-fold cross validation was performed to determine the 
optimal C parameter for that fold. Performance on the miR-E and UltramiR sets is 
reported on the outer held-out folds (Figure 2.5c). We trained our final classifier with 
the parameter setting C = 15 using all the miR-E and UltramiR data. This classifier was 
used to predict on all other data sets. 
 In order to calculate the final SplashRNA score, the potency scores for all 
shRNA are first calculated using the miR-30 classifier. If the score does not exceed the 
threshold theta, this partial score is the final score for the shRNA. If the score does 
exceed the threshold, the final score is a weighted combination of the predicted scores 
from the miR-30 and miR-E classifiers. 
 𝐹𝑖𝑛𝑎𝑙𝑠𝑐𝑜𝑟𝑒 𝑥 = 𝛼𝑆𝑉𝑀!"#!"(𝑥) 𝑖𝑓 𝛼𝑆𝑉𝑀!"#!"(𝑥) < 𝜃 𝛼𝑆𝑉𝑀!"#!" 𝑥  + (1− 𝛼)𝑆𝑉𝑀!"#$(𝑥) 𝑖𝑓 𝛼𝑆𝑉𝑀!"#!"(𝑥) ≥ 𝜃 
 
2.4  SplashRNA outperforms existing shRNA prediction methods 
 
When tested on miR-30 (Figure 2.6a-c) and miR-E (Figure 2.6d) data sets, 
SplashRNA clearly outperformed DSIR19, the current reference algorithm in the field 
(originally developed for siRNA design). The first classifier alone, SplashmiR-30 (auPR: 
0.615), shows the best performance. SplashRNA (auPR: 0.506) compromises slightly 
on miR-30 data to increase prediction accuracy on miR-E shRNAs, while still 
outperforming three other si/shRNA prediction tools (DSIR, seqScore, miR_Scan). 
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SplashRNA also outperformed the miR-30-based shERWOOD algorithm on the 
UltramiR set (Figure 2.7a), compared to its published maximum performance12.  
We also observed the high performance of SplashRNA in two large-scale biological 
RNAi screens45,46 run with shRNAs functionally equivalent to miR-E (Figure 2.7b,e)47, 
each of which tested ~25 preselected shRNAs per gene. In both screens, SplashRNA 
was able to retrospectively predict which shRNAs were potent and thus were enriched 
or depleted in the positive or negative selection screen, respectively. The positive 
selection data was selected from a large-scale pooled toxin sensitivity RNAi screen. 
Genes conveying sensitivity or resistance to the toxin were knocked down and the 
enrichment or depletion of shRNAs targeting each gene was measured. Similarly, the 
negative selection screen identified essential genes in K562 cells by measuring cell 
growth rate after knocking down genes. For each of the top 20 sensitivity genes and top 
50 essential genes, all shRNA prediction algorithms selected their top and bottom five 
sequences and the log2 fold changes for the selected shRNA were compared. 
SplashRNA was the only algorithm to achieve significant discrimination in the fold 
changes between the top and bottom predictions at p < 0.01 (p = 4.8e-4, one-sided 
Wilcoxon rank sum test) in the sensitivity gene study and achieved the most significant 
discrimination in the fold changes in the essential genes study (p = 1.8e-11, one-sided 
Wilcoxon rank sum test). Of note, SplashRNA also outperformed the other algorithms 
when selecting smaller or larger numbers of top sensitivity or essential genes from the 
screens (data not shown).  
SplashRNA predictions also showed equally good or better accuracy compared to larger 
sets of preselected shRNAs when tested on a subset of the negative-selection screen that 
included only a previously established set of ‘gold-standard’ essential genes46,48. The 
top ten SplashRNA predictions identified true positives significantly better than the 
bottom ten (P < 0.001, empirical permutation test), minimizing off-target hit 
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identification (Figure 2.7d). This indicates that the high performance of SplashRNA 
allows for fewer shRNAs to be tested per gene, decreasing the false discovery rate as 
well as the cost of the screen. 
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Figure 2.6: Performance of various shRNA prediction algorithms. 
(a) Precision-recall curves of SplashRNA performance on the external 
shERWOOD miR-30 dataset. (b) Precision-recall curves on the TILE dataset, 
comparing leave-one-gene-out nested cross-validation predictions from 
SplashRNA (auPR: 0.696) and SplashmiR-30 (auPR: 0.699) against the alternative 
prediction tools DSIR (auPR: 0.594), seqScore (auPR: 0.526) and miR_Scan 
(auPR: 0.449). (c) Prediction performance comparison of the indicated algorithms 
on the external mRas + hRAS Sensor dataset (Table 2.1). (d) SplashRNA 
performance on miR-E data. SplashRNA (auPR: 0.611) clearly outperforms the 
miR-30 classifier alone (auPR: 0.572) as well as three other prediction tools. 
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Figure 2.7: SplashRNA performance on in vivo screens.  
(a) SplashRNA and DSIR based re-ranking of shERWOOD selected UltramiR 
shRNAs targeting essential genes tested in a cell viability screen. X-axis: mean 
SplashRNA or DSIR score for equally sized groups (purple and blue dots, 20 groups) 
of 39 shRNAs each. Y-axis: Percent of shRNAs in each group that were potent. Right 
panel: published minimum, median, and maximum (Max) shERWOOD performance 
(green-brown dots). (b) Log2 fold changes in the top and bottom 5 retrospective 
potency shRNA predictions from SplashRNA and competing algorithms for the top 20 
most sensitizing genes from a large-scale toxin RNAi screen. (c) ROC curve 
comparing algorithms’ ability to identify “gold-standard” essential genes. The dashed 
line represents the 10% false positive rate (FPR) threshold.  (d) Log2 fold changes in 
top and bottom 5 shRNA predictions for the top 50 most essential genes from a large-
scale essential genes RNAi screen.  
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2.5 Targeting the relevant transcript space  
 
Robust shRNA prediction starts with the selection of the right transcript region. 
Analyses of unbiased TILE data showed that efficient shRNAs are more prevalent in 3′ 
UTRs compared to coding sequences and 5′ UTRs (Figure 2.8a), likely due to 
relatively high AU content (Figure 2.8b–d)10. Whereas 3′ UTRs often present ample 
design space because of their lengths, when validating top predictions in mouse 
fibroblasts, many shRNAs targeting the distal end of Pten resulted in minimal or no 
protein knockdown (Figure 2.8e, Table 2.2). Inspection of the Pten mRNA (NCBI, 
NM_008960) revealed that all these low-potency shRNAs targeted regions past 
polyadenylation signals (PASs), the use of which lead to shorter transcript variants49 
lacking the respective target sites (Table 2.2). Hence, to eliminate alternative cleavage 
and polyadenylation (ApA) as a source of non-functional shRNAs, we used PAS 
atlases50,51 to annotate the human and mouse reference transcriptomes (NCBI) and 
discard 3′ UTR portions that may be absent due to cleavage at a signal early in the 3′ 
UTR. Similarly, we report predictions only on the intersection of all transcript variants 
for each gene and filter multi-matching sequences.  
 Similarly, alternative splicing can lead to sequences being included or excluded 
in some gene transcripts. In order to ensure that a predicted shRNA will target all 
isoforms of a gene, we predict only on sequences that are present in all isoforms of a 
gene. Additionally, we do not predict shRNAs that span splice junctions to avoid mis-
targeting of the predicted shRNA due to variations in splicing. 
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Table 2.2: Polyadenylation sites in Pten gene affect observed shRNA knockdown. 
Start and End indicate shRNA site in base pairs on the 19th chromosome of the mm9 
build of the mouse genome. KD: qualitative degree knockdown observed in 
immunoblotting analyses of NIH/3T3s. PAS: previously published locations of poly-
adenylation sites, 19th chromosome, mm9, identified in NIH/3T3 and mouse ES cells by 
3P-seq. 2P-Seq: quantification of transcript expression levels measured by 2P-Seq. All 
shRNAs and PASs are ordered according to their position along the mouse genome 
(mm9). 
 
shRNA Start End KD PAS 2P-Seq Comment 
Pten.994 32850552 32850573 +++    
Pten.1523 32889925 32889946 +++    
Pten.1524 32889926 32889947 +++    
Pten.1965 32894404 32894425 +++    
    32894814 184.0 Major PAS 
Pten.3770 32896209 32896230 ++    
Pten.4524 32896963 32896984 +    
    32897818 47.0 Minor PAS 
Pten.5923 32898362 32898383 -    
Pten.6055 32898494 32898515 -    
Pten.6153 32898592 32898613 -    
Pten.6316 32898755 32898776 -    
Pten.7722 32900161 32900182 -    
    32900648 49.5 Poly(A) 
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Figure 2.8: Transcript selection.  
(a) Distribution of shRNA potency in functionally distinct transcript regions. Shown 
is the potency distribution of shRNAs in the unbiased TILE dataset that target the 
5’UTR, CDS or 3’UTR. Since these shRNAs were evaluated using the Sensor assay, 
their targets are not subject to alternative cleavage and polyadenylation (APA) 
and/or splicing events.  (b) A/U content of potent and weak miR-30 shRNAs from 
the unbiased TILE set. Potent shRNAs tend to have a higher proportion of A/U 
nucleotides (p < 2.2e-16, two-sided Kolmogorov-Smirnov test). (c) A/U content of 
functionally distinct transcript regions in the human genome. Shown are the A/U 
densities in 5’UTR, CDS and 3’UTR. (d) A/U content in mouse transcripts. (e) 
Alternative cleavage and polyadenylation (ApA) prevents potent shRNAs from 
inhibiting their putative target gene. Immunoblotting of Pten in NIH/3T3s 
transduced at single-copy with LEPG expressing the indicated shRNAs. Nine top 
predictions targeting the CDS or the 3’UTR after early ApA sites were compared 
alongside controls for their ability to suppress mouse Pten. Actb was used as loading 
control. 
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2.6 In vivo validation of de novo predicted shRNAs 
 
Testing an extensive set of individual de novo predictions targeting Pten, Bap1, Pbrm1, 
Rela, Bcl2l11, Axin1, NF2 and Cd9 under single-copy conditions13 by conventional 
western blot analysis (Figure 2.9a-f,h) or flow-cytometry based immunofluorescence 
of surface proteins (Figure 2.10a), we found that protein knockdown levels were very 
high: 91% of predictions (41/45) with a SplashRNA score of greater than 1 showed 
85% or higher protein knockdown (Figure 2.10b). Even in the case of human NF2, a 
gene with nine annotated transcript variants that share only 198 nucleotides (excluding 
the 5′ UTR, Figure 2.9g), the top eight SplashRNA predictions triggered 77–96% 
(median 89%) protein suppression under single-copy conditions (Figure 2.9h). 
Additionally, Cd9 knockdown analyses in mouse fibroblasts showed that SplashRNA 
clearly outperforms DSIR in de novo prediction and achieves near knockout levels 
comparable to CRISPR–Cas9 (Figure 2.10a).  
Extrapolating beyond the tested shRNAs, we calculated the proportion of genes 
for which SplashRNA would find at least five shRNAs above a given threshold (Figure 
2.10b). After shortening of transcripts due to ApA and considering only the intersection 
of all transcript variants per gene, we found that 87% of mouse genes and 81% of 
human genes have at least five shRNAs with SplashRNA scores above 1, corresponding 
to an 80% probability (e.g., four out of five shRNAs) of more than 85% knockdown at 
single-copy (Figure 2.10c).  
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Figure 2.9: Western blot validation of de novo SplashRNA predictions.  
All shRNAs were expressed using LEPG at single-copy conditions. β-Actin (Actb, 
ACTB) was used for normalization. Long (top) and short (bottom) exposures are 
shown. Immunoblotting of (a) Pten, (b) Bap1, (c) Pbrm1, (d) Rela, (e) Bcl2l11, (f) 
Axin1 in NIH/3T3s. C, miR-30 and miR-E control shRNAs. (g) Graphical depiction 
of human NF2 transcript variants. NF2 has nine variants with an intersection of only 
198 nucleotides, excluding the 5’UTR, rendering the prediction task especially 
difficult due to limited sequence space. (h) Predicting miR-E shRNAs for short 
transcripts. Immunoblotting of NF2 in A375s transduced with the indicated shRNAs 
targeting all nine NF2 variants.   
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Figure 2.10: SplashRNA comparison to CRISPR-Cas9 
(a) Comparison of SplashRNA and DSIR predictions against CRISPR-Cas9 
mediated suppression of Cd9 in mouse embryonic fibroblasts (MEFs). Shown are 
normalized (relative to the indicated controls) median anti-Cd9-APC fluorescence 
intensities of RRT-MEFs and CRT-MEFs expressing the indicated shRNAs or 
sgRNAs (Methods). The six top-scoring predictions from DSIR + Sensor rules 
(DSIR) or SplashRNA (ordered according to their respective scores) were 
compared to six sgRNA sequences. *, Cd9.1137 is the top prediction of both 
algorithms and was plotted twice for clarity. While DSIR predictions triggered Cd9 
knockdown with variable efficacy, SplashRNA predictions consistently induce 
strong Cd9 suppression, closely approaching knockout conditions. (b) Score 
distribution of fifth highest SplashRNA prediction for all human and mouse genes, 
indicating the proportion of genes with 5 predictions above a given score. 
Predictions were run only on the intersection of all transcript variants per gene and 
after shortening of transcripts to the most proximal PAS. The inset shows the score 
distribution of all human and mouse SplashRNA predictions. The kink in the curves 
represents the transition from SplashmiR-30 to combined SplashRNA scores. At least 
80% of genes have five shRNAs with prediction scores above 1 (dotted line). (c) 
Transfer function of SplashRNA score versus protein knockdown for all 62 de novo 
predicted shRNAs validated by immunofluorescence. Green triangles indicate the 
minimum knockdown for 80% of the predictions for a given SplashRNA score bin. 
Bins were defined to have a width of 0.5 with the leftmost bin starting at 0.25. For 
the bin centered on SplashRNA score = 1, 80% of predictions showed at least 86% 
protein knockdown. The expected knockdown for the top 80% of predictions (e.g. 
4/5 shRNAs) increases with the SplashRNA score. Together, 91% of predictions 
with a SplashRNA score >1 showed more than 85% protein knockdown. 
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2.7  Minimization of off-target effects 
 
Though RNAi triggers can be expressed as simple stem-loop shRNAs from RNA 
polymerase III (Pol-III) promoters in mammalian cells, such strategies can lead to off-
target effects associated with high shRNA expression levels35, likely due to saturation 
of the endogenous microRNA machinery52. Many Pol-III-based systems also suffer 
from inaccurate processing of precursor molecules34, yielding undesired mature small 
RNAs. In contrast, use of microRNA-embedded shRNAs expressed from RNA 
polymerase II (Pol-II) promoters results in accurate processing39,40 and can alleviate the 
toxic side effects36,37,53, especially when used at single genomic integration (single-
copy)11. Notably, highly potent miR-30-based shRNAs expressed at single-copy show 
the same low levels or absence of off-target effects as analogous weak and non-
functional sequences11. Hence, to develop an improved shRNA prediction algorithm, 
we focused on the optimized miR-E system that is based on the endogenous human 
MIR30A13.  
 Here, to determine the extent of sequence-based off-target effects we applied the 
GESS (Genome-wise Enrichment of Seed Sequence) algorithm54 to shRNAs validated 
by immunoblotting (Figure 9a-f,h), and to previously reported Sensor assay and gene 
expression microarray results10,11. We tested if potent shRNAs have more off-target 
effects than their weaker counterparts and if these targets have common sequences.  
First, to investigate sequence-based off-target effects, we analyzed RNA expression 
microarray data from Trp53−/− MEF cells infected at single or high copy with one of six 
Trp53 shRNAs11. Repetition of the published differential expression analysis found zero 
differentially expressed genes in the single-copy transfection setting relative to control 
experiments for either potent or weak shRNAs. In the high-copy transfection setting, 
702 genes were up-regulated and 326 genes were down-regulated in the cells with 
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potent shRNA with respect to control experiments (FDR < 0.05). Additionally, 2,437 
genes were up-regulated and 1,731 genes were down-regulated in cells transfected with 
weak shRNA relative to their controls. Therefore, potent shRNAs in this setting did not 
induce more gene expression changes than weak shRNAs but high-copy transfection 
did induce more off-target effects. Furthermore, the high-copy transfections of both the 
potent and weak shRNAs resulted in near identical lists of differentially expressed 
genes: 702 of 702 genes were significantly up-regulated in both lists and 324 of 326 
genes were significantly down-regulated in both lists. These intersections significantly 
overlapped (up-regulated: P < 2.2 × 10−16, down-regulated: P < 2.2 × 10−16, Fisher’s 
exact test), indicating that the main changes in gene expression are similar regardless of 
potency or shRNA sequence composition.  
Second, we applied the GESS algorithm54 to our validation shRNAs that were 
quantified by immunoblotting to determine potential sequence-based off-target effects 
in our current experiments. We attributed our shRNAs to three categories based on 
western blot knockdown: Low (less than 80% knockdown), Mid (between 80% and 
95% knockdown), High (95% knockdown or greater). For each gene and potency-level 
group, we ran GESS and found the genes that were potentially targeted by all the 
shRNAs in the group. We found no statistically significant off-targeted genes by GESS 
(FDR < 0.1). We also tested if the level of potency is associated with the number of 
potential off-target genes as measured by the number of perfect 7-mer seed matches 
(nucleotides 2–8). Grouping shRNAs into three groups by percent knockdown, High: 
>95%, Medium: 90–95%, and Low: 80–90%, and testing for a significant difference in 
the number of gene seed matches found no statistically significant difference between 
any pair of groups (P = 0.74, 0.53, and 0.73 for Low vs. Medium, Low vs. High, and 
Medium vs. High, respectively).  
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Third, we calculated all perfect 22-mer multi-mapping matches transcriptome-
wide, since perfect matching of an shRNA to several genes would be highly 
undesirable. Consequently, we incorporated an additional feature into the SplashRNA 
algorithm and web site that alerts the user if a predicted hairpin perfectly matches 
multiple genes in the human or mouse transcriptomes (hg38, mm10). 
 
2.8 Discussion 
 
Building on our Sensor assay and the optimized miR-E backbone, here we have 
established a robust algorithm to predict ultra-potent microRNA-based shRNAs 
targeting nearly any gene. SplashRNA is able to accurately predict the potency of 
independently validated and novel shRNAs and outperforms existing algorithms. Our 
sequential predictor approach facilitates the integration of biased and unbiased data sets 
and can serve as a blueprint for other prediction problems. An open source 
implementation of SplashRNA is accessible at http://splashrna.mskcc.org. The website 
can directly predict on custom sequences or mouse and human Entrez Gene IDs. When 
using gene IDs, the tool integrates cleavage and poly-adenylation signal annotations and 
calculates the intersection of all transcript variants to predict only on constitutive 
sequence regions. To facilitate the use of SplashRNA, all transcript annotations and 
predicted shRNAs are graphically displayed online and can be downloaded in batch. 
 
 
 
 
 
 
42 
CHAPTER 3  
CHROMATIN STATES DEFINE TUMOR-SPECIFIC T CELL DYSFUNCTION 
AND REPROGRAMMING 
Portions of this chapter first appeared in Philip et. al.55 and were written in collaboration 
with Mary Philip, Andrea Schietinger, and Christina Leslie. 
 
3.1 Introduction 
 
Tumor-specific CD8 T cells (TST) are often found within solid tumors, but tumors 
progress despite their presence, suggesting that these TST are dysfunctional56. The 
clinical success of immune checkpoint blockade (for example, PD1/PDL1- and CTLA4-
blocking antibodies) and adoptive T cell therapy in a subset of patients with cancer 
demonstrates the great potential of TST57; however, important questions remain, 
including how to predict which patients will respond to therapy and precisely which 
TST mediate clinical responses58-60. Moreover, an unmet need is the development of 
interventions for tumors that are refractory to checkpoint blockade despite having ample 
TST infiltration.  
We previously demonstrated that in the early stages of tumorigenesis, TST become non-
responsive, exhibiting the phenotypic, functional, and transcriptional features of tumor-
reactive tumor-infiltrating lymphocytes (TIL) from late-stage human solid tumors30. 
TST dysfunction is initially reversible but ultimately becomes irreversible, even after 
removal of dysfunctional T cells from the tumor microenvironment and multiple rounds 
of cell division30. We hypothesized that this heritable, signal-independent dysfunctional 
state is epigenetically imprinted. The epigenetic programs that regulate normal 
differentiation of innate and adaptive lymphocytes have been described61-64. However, 
the epigenetic programs regulating T cell differentiation and dysfunction in tumors are 
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not known. In this study, we used the assay for transposase-accessible chromatin with 
high-throughput sequencing (ATAC-seq)32 to assess genome-wide chromatin 
accessibility changes during T cell differentiation in tumors compared to acute 
infection. 
 
3.2 CD8 T cell chromatin changes during infection 
 
We transferred congenically marked naive (N; CD44loCD62Lhi) TCRTAG cells (specific 
for SV40 large T antigen epitope I (TAG))65 from TCRTAG transgenic mice into wild-
type C57BL/6 mice, which were immunized one day later with a recombinant Listeria 
monocytogenes strain expressing TAG (LmTAG)30,66. TCRTAG cells were re-isolated, 
phenotypically and functionally characterized, and underwent ATAC-seq and RNA-seq 
at 5, 7 (effectors; E5, E7) and 60+ days (memory; M) after immunization (Figure 1.4a). 
Figure 3.1: Flow cytometric analysis of characteristic markers after LmTAG 
stimulation.  
Naïve TCRTAG (N; Thy1.1+) were transferred into B6 (Thy1.2+) mice which were 
immunized with LmTAG one day later. At days 5, 7, and 60+ post LmTAG, effector (E5 
and E7) and memory (M) T cells were isolated from spleens and assessed for phenotype 
and function. Flow cytometric analysis of CD44, CD62L, IL7Rα, TBET, and GZMB 
expression ex vivo (upper panel), and intracellular IFNγ and TNFα production and 
CD107 expression after 4-hour ex vivo TAG peptide stimulation (lower panel). Flow 
plots are gated on CD8+ Thy1.1+ cells.  
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N, E5, E7, and M expressed characteristic activation, homing and cytokine receptors 
(CD44, CD62L, IL7R), transcription factors (TBET), cytotoxic molecules (GZMB, 
CD107), and pro-inflammatory cytokines (IFNγ, TNFα) (Figure 3.1).   
 Using DESeq267 to assess differential chromatin accessibility, we found that 
substantial chromatin remodeling occurred as cells differentiated from the N to the 
Figure 3.2: Chromatin accessibility in normal CD8 T cells  
(a) Chromatin accessibility heat map grouped by differential accessibility patterns. 
Each row represents one of 8,654 selected peaks (significantly differentially accessible 
between at least one sequential cell comparison; FDR < 0.05, absolute log2 fold 
change > 2).  (b) MA plot, naive (N) to day 5 effectors (E5) transition, mean read 
counts for all atlas peaks versus log2 ratios of peak accessibility. Significantly 
differentially accessible peaks are shown in red (FDR < 0.05).  (c) ATAC-seq (top) 
and RNA-seq (bottom) signal profiles of Prf1 and Tnf in naive, effectors, and memory 
TCRTAG cells during acute LmTAG infection.  
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effector state (E5) (37,038 ATAC-seq peaks were differentially accessible during this 
transition), with substantially less remodeling from E5 to E7 and E7 to M (23 and 6,459 
differentially accessible regions, respectively, FDR < 0.05, Figure 3.2a,b). In naïve 
cells, effector gene loci such as Prf1 and Tnf shared highly accessible chromatin and 
basal transcriptional activity with effector and memory cells (Figure 3.2c), consistent 
with the presence of activation-associated histone marks previously shown at these loci 
in naive T cells68,69 
We analyzed accessibility changes during the N to E5 transition in loci 
associated with early and late TCR-response genes, as defined by the Immunological 
Genome Project70. Early-response genes showed many fewer accessibility changes 
compared to late-response genes (p < 1e-16), implying that they may not require 
Figure 3.3: Activation of early response genes.  
ATAC-seq signal profiles (left) and z-score normalized RNA expression (right) of the 
early response genes Ldha (top) and Mki67 (bottom) in N, E5/E7, and M TCRTAG cells 
during acute LmTAG infection (blue line, current data set) overlaid with expression 
data from Immunological Genome Project (red line). 
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chromatin accessibility changes to activate expression. For example, Ldha (encoding 
LDHA, required for the metabolic shift to aerobic glycolysis and IFNγ production69) 
and Mki67 (encoding KI67, required for chromosome segregation during mitosis71) loci 
require no change in chromatin accessibility to be rapidly induced after TCR 
stimulation (Figure 3.3). 
Memory T cells exhibit more rapid and robust effector function upon antigen re 
-encounter compared to naive T cells72. K-means clustering of RNA expression patterns 
Figure 3.4: Linked k-means clustered RNA-seq and ATAC-seq heatmaps.  
Left, K-means clustered (K=6, row-normalized) RNA-seq data for 1,758 
differentially expressed genes (log2(FC)>1, FDR<0.05, base mean log2 expression ≥ 
10). Right, heat map of differentially accessible peaks (FDR < 0.05, log2(FC) > 1) 
associated with genes in K-means clusters 1 and 3. Right scale: z-scored Log2 read 
counts, Left scale: Log2 read counts per 20bp bin.  
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(Figure 3.4, left) revealed two trends: transient gene activation or down-regulation in 
E5/E7 but not M (clusters 1, 2, 5, 6), and stable gene activation or down-regulation in 
E5, E7, and M (clusters 3 and 4). Surprisingly, chromatin accessibility of loci identified 
as transient was largely similar in effector and memory cell states (Figure 3.4, right), 
indicating that memory cells are retaining an “effector-like” chromatin state. This 
retained chromatin state may permit basal transcription of certain effector genes (cluster 
3) such as Ifng, whereas other genes are transcriptionally silent but poised for rapid re-
expression upon TCR activation (cluster 1, Gzma) (Figure 3.4, right).  
 
3.3 Chromatin state dynamics of TST dysfunction 
 
We next assessed chromatin-state dynamics in TST over the course of tumorigenesis 
using the previously described tamoxifen-inducible, autochthonous liver cancer model 
(AST-Cre-ERT2) in which TAG is a tumor-specific antigen30. AST-Cre-ERT2 mice 
initially develop pre-malignant lesions which progress into hepatocellular carcinoma by 
Figure 3.5: Flow cytometric analysis of inhibitory markers in TST.  
Immunophenotype and cytokine production (grey, no peptide control) (n=8 total, 
n=2 per time point). Each symbol represents an individual mouse. *P=0.0002 
(Student’s t-test); NS, not statistically significant. 
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day 60–9030. We transferred congenically marked naive TCRTAG cells (N, the same as N 
in Figure 1.4a) into AST-Cre-ERT2 mice one day before administration of tamoxifen 
and then analyzed TCRTAG cells at different time points (Figure 1.4b). Liver-infiltrating 
TCRTAG cells down-regulated CD62L, uniformly expressed activation markers CD44 
and inhibitory receptors PD1 and LAG3, and failed to produce IFNγ or TNFα (Figure 
3.5). Massive chromatin remodeling occurred by day 5: about 50,000 ATAC-seq 
regions were significantly differentially accessible between day 5 and naïve cells, 
followed by a second wave of remodeling between days 7 and 14, resulting in 25,000 
differentially accessible regions (FDR<0.05, Figure 3.6a). Notably, after this second 
wave, few accessibility changes occurred, even after progression to established tumors 
at day 60+ (Figure 3.6a,b). Thus, TST differentiated through two discrete chromatin 
states: an initial state (L5, L7), and a later state established by day 14 and persisting 
thereafter. Many of the ATAC-seq peaks that were gained or lost during these 
transitions were in intronic and intergenic regions (potential enhancer peaks), whereas 
peaks present across all CD8 T cells were predominantly in promoter regions (Figure 
3.6c, bottom); this pattern was also present in functional CD8 T cell differentiation 
(Figure 3.6c, top).  
TCRTAG cells in malignant lesions followed a distinct epigenetic trajectory compared to 
TCRTAG cells in acute infection (L5 versus E5; Figure 3.6b). Many accessibility 
changes occurred exclusively in the transition from N to early dysfunctional (N to L5, 
3641 opening, 3213 closing) or N to functional effector (N to E5, 9696 opening, 6271 
closing). Two intergenic ATAC-seq peaks near the Ifng locus that opened during 
normal effector differentiation were inaccessible in dysfunctional TCRTAG cells (Figure 
3.7, right), indicating potential dysregulation of Ifng. Additionally, an intergenic peak 
23.8 kb upstream of the PD1-encoding Pdcd1 locus was accessible in all tumor-
associated T cells (L5 to L60+), but not in N, E5/E7, or M (Figure 3.7, left). This 
 
 
 
49 
region was also described in exhausted T cells in chronic viral infection73-75 indicating a 
potential mechanistic similarity between tumor-associated T cell dysfunction and 
exhaustion associated with chronic viral infection.  
Figure 3.6: Overview of chromatin accessibility in TST  
(a) Chromatin accessibility heat map (15,275 differentially accessible regions, 
FDR<0.05, absolute log2 fold change > 1).  (b) Principal component analysis (PCA) 
of peak accessibility in naive TCRTAG cells (N; grey) during normal differentiation 
(green) and during tumorigenesis (blue). (c) Pie charts show proportions of 
reproducible ATAC-seq peaks in exonic, intronic, intergenic, and promoter regions 
(left, distribution for all peaks in the atlas). Green box: normal CD8 T cell 
differentiation during LmTAG immunization; Blue box: differentiation to 
dysfunction in progressing tumors. Variable: significant change in at least one cell 
type comparison. Common: no significant change in any cell type comparison.  
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 To determine which transcription factors were associated with the transition 
from N to D5 relative to normal differentiation from N to E5, we tested whether 
accessibility of predicted transcription factor targets changed significantly in these 
transitions (Figure 3.8a). Predicted NFATC1-binding sites, including those associated 
with genes encoding inhibitory receptors and negative regulators such as Ctla4, Pdcd1, 
Tigit, Socs1, and Cblb and transcription factors Egr1 and Egr2, had increased 
accessibility in dysfunctional L5 relative to naïve cells (Figure 3.8a). NFAT 
transcription factorfamily members, particularly NFATC1 and NFATC2, are important 
regulators of T cell development and function76, as well as exhaustion in chronic viral 
infections77. Potential target genes whose binding sites opened in L5 relative to E5 
(Figure 3.8b) were significantly more likely to be more highly expressed in L5 relative 
to E5 and the opposite was true for target genes containing binding sites that closed in 
L5 relative to E5 (P < 1e-16 for both comparisons, Fisher’s exact test), consistent with 
Figure 3.7: ATAC-seq signal in Pdcd1 and Ifng loci in normal and TST cells.  
Peaks present only in TST cells or normal cells are highlighted in red and blue, 
respectively. 
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the hypothesis that differential accessibility of these NFATC1 binding sites leads to 
downstream differential expression of predicted targets.  
 
3.4 Chromatin states correlate with reprogrammability  
 
Notably, the discrete chromatin states in dysfunctional TCRTAG cells correlate 
temporally with our previous observation that L8 but not L35 were capable of regaining 
effector function30. Indeed, when we re-isolated TCRTAG cells from liver lesions and 
cultured them in vitro with IL-15 (Figure 3.9a), previously shown to induce 
Figure 3.8: Transcription factor accessibility in naïve to L5 transition  
(a) The 20 most significantly enriched transcription factor motifs in peaks opening (red) 
and closing (blue) between L5 and E5. (b) Scatterplot comparing the changes in peak 
accessibility for all peaks containing the NFATC1 motif during the transition from N to 
E5 TCRTAG cells during acute listeria LmTAG infection versus N to L5 in pre-malignant 
lesions. Highlighted are NFATC1 target peaks associated with genes encoding negative 
regulatory transcription factors and inhibitory receptors. Some genes, for example, Cblb 
and Klf4, had multiple NFATC1 target peaks, including peaks that decreased in 
accessibility. 
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proliferation and restore effector function in tumor-reactive CD8 T cells78,79, L5 and L7 
regained the ability to produce IFNγ and TNFα, but TCRTAG cells isolated at day 12 and 
after did not (Figure 3.9a). Thus the first dysfunctional state is plastic, but with 
concomitant chromatin remodeling between days 7 and 14, becomes fixed. 
Genomic regions containing binding motifs of TCF family members closed during the 
transition from the plastic (L7) to fixed (L14) states, whereas sites containing motifs for 
E2F, ETS, and KLF family members opened (Figure 3.9b). Additionally, TCF1 
(encoded by Tcf7) protein levels decreased between L7 and L14 (Figure 3.9c), and 
analysis of closing peaks showed enrichment for associated WNT receptor signaling 
pathway genes, regions upstream of TCF family transcription factors, as well as 
Figure 3.9: Tumor-associated T cell dysfunction occurs in two states  
(a) Top, cytokine production by L5, L12, and L17 after 3 days in vitro IL-15 culture 
(grey, no peptide control). Bottom, IFNγ production ex vivo (circles) or after 3–4 days 
IL-15 in vitro culture (triangles). Pooled from three experiments. (b) The 20 most 
significantly enriched transcription factor motifs in peaks opening (red) and closing 
(blue) between L7 and L14. (c) TCF1 expression (MFI; mean fluorescence intensity). 
Each symbol represents individual mouse. Mean ± s.e.m. shown 
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cytokine response, TCR signaling, and T cell differentiation pathway genes (Table 3.1). 
Among the TCR signaling genes most up-regulated during the L7–L14 transition were 
negative regulators such as Cish1 and Socs2, whereas co-stimulatory molecule genes 
such as Icos and Cd28 were down-regulated. 
We next used an in vivo pharmacologic strategy to validate the predicted role of 
NFAT and TCF in TST dysfunction. FK506 is an immunosuppressant that inhibits 
NFAT nuclear translocation and downstream gene activation80,81, and we used 25% of 
the full immunosuppression dose to partially down-regulate NFAT activity without 
completely blocking T cell activation and/or effector function. TWS119, a GSK3β 
inhibitor, enhances differentiation of CD8 T cells to memory cells through WNT/ TCF1 
activation82. We treated TCRTAG-adoptively transferred AST-Cre-ERT2 mice with 
FK506 alone or in combination with TWS119 (Figure 3.10a) and found that L10 TST 
from FK506 and FK506/TWS119-treated mice had decreased expression of the 
NFATC1 targets PD1 and LAG3, increased levels of TCF1 and EOMES (Figure 
3.10b), and were more efficiently reprogrammable (Figure 3.10c) compared to controls 
or TWS119 alone (data not shown). 
 
Table 3.1: GO terms enriched in regions closing in L7 to L14 transition 
Selected enriched biological process gene ontology (GO) terms associated with 
chromatin regions which significantly lost chromatin accessibility during the L7 to L14 
transition as determined by GREAT analysis. 
 
Biological process GO term Rank FDR 
Cellular response to cytokine stimulus 66 6.93E-14 
Positive regulation of T cell activation 75 7.05E-13 
Positive regulation of T cell differentiation 143 3.71E-10 
Regulation of canonical Wnt receptor signaling pathway 231 4.77E-08 
Positive regulation of T cell receptor signaling pathway 306 4.63E-07 
Regulation of lymphocyte differentiation 312 5.38E-07 
Regulation of interferon-gamma production 368 1.99E-06 
Regulation of transcription regulatory region DNA binding 459 1.35E-05 
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Figure 3.10: Pharmacological targeting of NFAT and Wnt/β-catenin signaling 
prevents TST differentiation to the fixed dysfunctional state in vivo.  
(a) Experimental scheme. Naive TCRTAG cells (Thy1.1+) were transferred into AST-
Cre-ERT2 (Thy1.2+) mice which were treated with tamoxifen (tam) one day later. 
At days 2–9 mice were treated with the calcineurin inhibitor FK506 (2.5 mg kg−1 
per mouse) alone (FK506 treatment group; orange), or in combination with the 
GSK3β inhibitor TWS119 (0.75 mg per mouse; days 5–8) (FK506 + TWS119 
treatment group; green), or PBS/DMSO (control group; blue) as indicated. At day 
10, TCRTAG cells were isolated from livers and assessed for phenotype and 
function. (b) Flow cytometric analysis of CD44, PD1, LAG3, TCF1, and EOMES 
expression of TCRTAG cells. (c) Production of IFNγ and TNFα by TCRTAG cells 
isolated at day 10 (left panel; ex vivo), and after 3 days IL-15 in vitro culture (right 
panel). Each symbol represents an individual mouse. Data show mean ± s.e.m.; P 
values calculated using unpaired two-tailed t-test.  
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3.5 Surface proteins associated with chromatin states  
 
We wanted to determine if any surface proteins could be used to differentiate between 
TSTs in plastic and fixed dysfunctional states and thus indicate reprogrammability of 
heterogeneous TIL. PD1 and LAG3, two inhibitory receptors, are similarly expressed 
by both plastic (L5, L7) and fixed (L14+) dysfunctional TST (Figure 3.5) and thus not 
informative in this regard. We identified membrane protein genes differentially 
expressed between plastic (L5, L7) and fixed (L14 to L60+) dysfunctional TCRTAG cells 
(Figure 3.11a) and found several markers not previously associated with tumor-induced 
T cell dysfunction. Plastic (L5, L7) TCRTAG cells had low expression of CD38, CD101, 
and CD30L and high expression of CD5, whereas fixed (L14, L28) TCRTAG cells had 
the opposite pattern (Figure 3.11b). Consistent with its expression, the Cd38 locus 
contained intergenic and intronic ATAC-seq peaks only accessible in fixed-
dysfunctional TST (Figure 3.12). Moreover, TCRTAG cells from FK506 and 
FK506/TWS119-treated mice expressed low CD38 and CD101 compared to controls, 
correlating with their improved reprogrammability (Figure 3.10d). To test whether 
these markers could identify reprogrammable T cells within a heterogeneous TST 
population, we sorted CD38loCD101lo and CD38hiCD101hi TST from PD1hi L14 cells 
and assessed reprogrammability (3 days in vitro IL-15). CD38loCD101lo L14 regained 
the ability to produce IFNγ and TNFα, but CD38hiCD101hi L14 did not (Figure 3.11c). 
To determine if these findings could be applied to other tumor histologies and/or 
T cell specificities, we repeated these experiments using mouse B16F10 (B16) 
melanoma cells expressing ovalbumin (B16-OVA), a model antigen recognized by 
OVA-specific OT1 CD8 T cells (TCROT1 cells). Naïve congenically marked TCROT1 
cells were adoptively transferred into B16-OVA tumor-bearing B6 mice. Tumor-
infiltrating TCROT1 cells up-regulated CD44, PD1, and LAG3, down-regulated CD62L, 
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and lost the ability to produce IFNγ and TNFα (Figure 3.13a). At later stages, 
dysfunctional TCROT1 cells expressed high levels of CD38 and CD101 and down-
regulated CD5 relative to day 5 dysfunctional TCROT1 cells (Figure 3.13b). Moreover, 
late dysfunctional TCROT1 cells at day 25 could not regain the ability to produce IFNγ 
or TNFα, in contrast to early dysfunctional TCROT1 cells at day 5 (Figure 3.13c). 
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Figure 3.11: Cell surface markers for dysfunctional state transition  
(a) RNA-seq expression (row-normalized) for the 50 most significant differentially 
expressed genes encoding membrane proteins. (b) CD38, CD101, CD30L and CD5 
expression; representative of 3 independent experiments. (c) Cytokine production by 
sorted CD38loCD101lo (blue) and CD38hiCD101hi (red) L14 after 3 days IL-15 in vitro 
culture. Similar data obtained with sorted L10 in independent experiment. Each symbol 
represents an individual mouse. 
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Figure 3.13: B16-OVA model  
(a) Immunophenotype of and cytokine production by TCROT1 cells re-isolated 
from established B16-OVA tumors 5 (D5) and 13 (D13) days after transfer. (b) 
CD38, CD101 and CD5 expression on day 5 and day 13 TCROT1 cells. (c) 
Cytokine production by day 5 and day 21 TCROT1 cells after 3 days of IL-15 in 
vitro culture. Each symbol represents an individual mouse. Mean ± s.e.m. shown. 
Figure 3.12: ATAC-seq signal profile across the Cd38 locus.  
Peaks accessible only in fixed dysfunctional cells highlighted in pink; 
activation-associated peaks highlighted in blue. 
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3.6 Memory T cells enter fixed dysfunctional state in tumor 
 
As memory cells (M; Figure 1.4a) have been previously activated and their chromatin 
accessibility landscape is similar to that of functional effector cells, we hypothesized 
that they may be resistant to the differentiation to dysfunction we observed in naïve 
cells in the tumor environment. We transferred TCRTAG memory cells into AST-Alb-
CreT2 mice (in which hepatocytes express TAG from birth30) bearing established 
hepatocellular carcinomas and, one day later, immunized with LmTAG (Figure 3.14a). 
By day 7, tumor-infiltrating memory T cells (ML7) rapidly up-regulated PD1 and 
LAG3 and progressively lost effector function (Figure 3.14b). ATAC-seq revealed that 
M cells followed a similar epigenetic trajectory as the N cells in early malignant lesions 
(Figure 3.14c,d) and remarkably, by day 35, the chromatin state of transferred M cells 
was nearly identical to that of N at day 35 in early malignant lesions (ML35 and L35, 
respectively; Figure 3.14d). Dysfunctional M cells displayed the same gain and loss of 
ATAC-seq peaks in critical gene loci including Pdcd1, Ctla4, Cd38, Tcf7, and Ifng 
(Figure 3.15a). Changes in surface protein expression (CD38, CD101, CD30L, and 
CD5) between ML7 and ML14 were similar to those seen with N (L7 and L14, 
respectively) (Figure 3.15b). We obtained similar results when LmTAG immunization 
after adoptive transfer was omitted (Figure 3.14c,d). 
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Figure 3.14: Memory CD8 T cells in established tumors  
(a) Experimental scheme (b) Cytokine production of M cells isolated from liver 
tumors. (c) PCA of peak accessibility in TCRTAG cells during acute infection (green), 
tumorigenesis (blue), and memory TCRTAG cells in established tumors (red). 
Diamonds represent adoptively transferred memory cells without LmTAG 
immunization (d) Chromatin accessibility heat map. Each row represents 1 of 11,698 
selected peaks (differentially accessible between any sequential cell comparison; FDR 
< 0.05, log2(FC) > 2). Shown are ±1kb from the peak summit (2kb total per region).  
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Figure 3.15: Dysfunctional memory cells  
(a) ATAC-seq signal profiles of Pdcd1, Ctla4, Cd38, Tcf7, and Ifng genes for naive 
(N; grey), memory (M; green), L7, L14, L35 (blue series), and ML7, ML14, and 
ML35 (red series) TCRTAG cells. Red boxes highlight peaks that become accessible in 
dysfunctional T cells compared to naive and memory; blue boxes highlight peaks that 
become inaccessible in dysfunctional TCRTAG cells compared to naive and memory. 
(b) CD38, CD101, CD30L, and CD5 expression in ML7, ML14, ML21. Inset numbers 
show MFI.  
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3.7 Chromatin accessibility in human TILs 
 
Finally, we examined chromatin states of human CD8 TIL and peripheral blood 
lymphocytes from healthy donors. We carried out ATAC-seq on naive (N; 
CD45RA+CD45RO−), effector memory (EM; CD45RA−CD45RO+CD62Llo), and 
central memory (CM; CD45RA−CD45RO+CD62Lhi) CD8 peripheral blood 
lymphocytes from healthy donors and PD1hi CD8 TIL isolated from human melanoma 
and non-small-cell lung cancer tumors (Figure 3.16a). Human N cells had a distinct 
chromatin state as compared to EM and CM, which were similar (Figure 3.16b,c), 
Figure 3.16: Normal human T cells and tumor-infiltrating lymphocytes  
(a) Peripheral blood lymphocyte sorting scheme for naive (N), effector memory (EM), 
central memory (CM) CD8 T cell populations (left), and PD1hi CD8 TIL from 
patients with melanoma or non-small-cell lung cancer.  (b) PCA using normalized 
read counts from all reproducible ATAC-seq peaks in human healthy donor peripheral
 blood lymphocytes and PD1hi TIL from melanoma and non-small-cell lung cancer 
tumors. (c) Differentially accessible ATAC-seq peaks grouped by DESeq-defined 
differential accessibility pattern. Each column represents one biological replicate.  
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though distinct accessibility patterns in genes such as SELL. Multiple peaks were gained 
or lost only in PD1hi TIL, including peaks in IFNG, EGR2, CD5, and CTLA4 (Figure 
3.17a). We compared the accessibility changes in peaks outside of promoter regions 
that occurred during functional and dysfunctional mouse CD8 T cell differentiation with 
those observed in human peripheral blood lymphocytes and PD1hi TIL and found that 
human PD1hi TIL had the greatest correlation in peak accessibility changes with fixed 
dysfunctional (late-stage) mouse TST, relative to their respective naïve cells (Figure 
3.17b). For example, the TCF7/Tcf7 locus showed similar intergenic and intronic peak 
accessibility changes in human PD1hi TIL and mouse fixed-dysfunctional TCRTAG cells 
(Figure 3.17c). A subset of PD1hi TIL expressed higher levels of CD38 and CD101 and 
lower levels of CD5 (Figure 3.18), suggesting that these markers could potentially be 
used to identify T cells that are amenable to therapeutic reprogramming in human 
tumors.  
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3.8 Discussion 
 
In this study, we define the chromatin state dynamics underlying tumor-specific T cell 
dysfunction over the course of tumorigenesis. Naive TST encountering tumor antigen in 
pre-malignant lesions differentiated to an initially plastic, therapeutically 
reprogrammable chromatin state, then transitioned to a fixed dysfunctional chromatin 
state that did not undergo further remodeling, even after progression to large established 
tumors. The rapid induction of dysfunction early during tumorigenesis without 
progression through an effector state resembles peripheral self-tolerance induction83,84. 
Surprisingly, memory TST differentiated to the same fixed dysfunctional chromatin 
state in tumors, suggesting that antigen exposure in tumors can overwrite pre-existing 
epigenetic programs regardless of the initial differentiation state.  
We identified surface markers, including CD101 and CD38, which were 
associated with discrete dysfunctional chromatin states and demarcated reprogrammable 
from non-reprogrammable PD1hi T cells within heterogeneous TIL populations, a 
finding of important potential clinical relevance, and human PD1hi TIL showed 
heterogeneous expression of these markers. In patients who do not respond to immune 
checkpoint blockade (non-responders), PD1hi TIL may be in a fixed dysfunctional state, 
Figure 3.18: Characterization of normal human T cells and TILs.  
CD38, CD101 and CD5 expression in human CM (green) and PD1hi TIL (blue). 
Each symbol represents an individual healthy donor/patient. Mean ± s.e.m. shown. 
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in contrast to responders whose PD1hi TIL are in a plastic state, amenable to 
reprogramming. Our studies on the epigenetic and transcriptional programs underlying 
TST dysfunctional states and therapeutic reprogrammability point to new targets and 
strategies to transform TST into potent anti-tumor agents. 
 
3.9 Methods 
 
ATAC-seq processing pipeline: Raw ATAC-seq reads were trimmed and filtered for 
quality using Trim Galore! v0.4.085, powered by CutAdapt v1.8.186 and FastQC 
v0.11.387. Paired-end reads were aligned using Bowtie2 v2.2.588 against either mm10 or 
hg38 and non-uniquely mapping reads were removed. To correct for the fact that the 
Tn5 transposase binds as a dimer and inserts two adapters in the Tn5 tagmentation 
step89, all positive-strand reads were shifted 4bp downstream and all negative-strand 
reads were shifted 5bp upstream to center the reads on the transposon binding event32. 
We then pooled the shifted reads by sample type and identified peaks using MACS290 
with a threshold of FDR-corrected P < 1×10−2 using the Benjamini–Hochberg 
procedure for multiple hypothesis correction. As called peaks may be caused by noise in 
the assay and not reflect true chromatin accessibility, we calculated an irreproducible 
discovery rate (IDR)91 for all pairs of replicates across a cell type. The IDR is an 
estimate of the threshold where two ranked lists of results, in this case peak calls ranked 
by P value, no longer represent reproducible events. Using this measure, we excluded 
peaks that were not reproducible (IDR< 5×10−3) across at least one pair of replicates in 
each mouse or human cell type.  
 
ATAC-seq atlas creation: Peaks found reproducibly in each mouse cell type were 
combined to create a genome-wide atlas of accessible chromatin regions. Reproducible 
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peaks from different samples were merged if they overlapped by more than 75%. To 
create the atlas of accessible peaks for the human samples, reproducible peaks from the 
normal human cell types (HN, HCM, and HEM) and the tumor-derived cells (PD1hi) 
were combined. There was greater variation between the human TIL samples than 
between T cell samples from healthy donors; this led to fewer reproducible peaks being 
called in the TIL samples. Like the mouse atlas, peaks overlapping by more than 75% 
were merged in the human atlas. Numbers of called peaks and reproducible peaks for 
each sample type are listed in Table 3.2.  
 
Assignment of ATAC-seq peaks to genes: The RefSeq transcript annotations of the 
hg38 version of the human genome and the mm10 version of the mouse genome were 
used to define the genomic location of transcription units. For genes with multiple gene 
models, the longest transcription unit was used for the gene locus definition. ATAC 
peaks located in the body of the transcription unit, together with the 2-kb regions 
upstream of the TSS and downstream of the 3′ end, were assigned to the gene. If a peak 
was found in the overlap of the transcription units of two genes, one of the genes was 
chosen arbitrarily. Intergenic peaks were assigned to the gene with a TSS or 3′ end that 
was closest to the peak. In this way, each peak was unambiguously assigned to one 
gene. Peaks were annotated as promoter peaks if they were within 2kb of a transcription 
start site. Non-promoter peaks were annotated as intergenic, intronic or exonic 
according to the relevant RefSeq transcript annotation.
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Table 3.2: Number of peaks per cell type 
Number of called ATAC-seq peaks (MACS2 p=0.01) and number of reproducible peaks 
(IDR<0.001) for each cell state. 
 
 Called peaks Reproducible peaks 
N 91,255 46,089 
E5 87,914 44,520 
E7 109,081 49,625 
M 100,110 27,191 
L5 105,022 43,960 
L7 92,692 41,322 
L14 91,396 44,648 
L21 79,556 40,264 
L28 84,994 45,055 
L35 82,536 44,660 
L60+ 76,228 38,316 
ML7 110,847 38,753 
ML14 86,946 30,798 
ML35 81,446 44,508 
ML7_noLM 101,478 45,844 
ML14_noLM 95,763 51,534 
   Human N 133,716 32,675 
Human CM 91,745 36,283 
Human EM 88,521 29,666 
Human PD1hi_1 TIL 73,748 - 
Human PD1hi_2 TIL 87,029 - 
Human PD1hi_3 TIL 98,554 - 
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ATAC-seq peak atlas summary: We found a total of 75,689 reproducible ATAC-seq 
peaks in the mouse samples. Examining genomic locations, 39.6% of the peaks were 
found in introns, 36.3% were found in intergenic regions, 22.1% were found in 
promoters and 2.1% were found in exons. In the human samples, we found a total of 
42,104 reproducible ATAC-seq peaks. Among these peaks, 34.0% were found in 
introns, 29.9% were found in intergenic regions, 34.0% were found in promoters, and 
2.0% were found in exons. Chromosome-wide genomic coverage for all (autosomal) 
chromosomes and all samples was examined and no systemic bias was observed.  
 
Principal component analysis: PCA plots were generated using read counts against all 
mouse or human atlas peaks. These read counts were processed using the variance-
stabilizing transformation built into the DESeq2 package92.  
 
Differential peak accessibility: Reads aligning to atlas peak regions were counted 
using the summarizeOverlaps function of the R packages GenomicAlignments v1.2.2 
and GenomicRanges v1.18.493. Differential accessibility of these peaks was then 
calculated for all pairwise comparisons of cell types using DESeq2 v1.6.392. 
 
Peak heat maps and genome coverage plots: The ATAC-seq peak heat maps were 
created by pooling the DESeq size-factor normalized read counts per atlas peak across 
replicates of ATAC-seq data and binning the region ±1kb around the peak summit in 
20bp bins. To improve visibility, bins with read counts greater than the 75th 
percentile+1.5×IQR were capped at that value. All analysis was performed using the 
original uncapped read counts. Genome coverage plots were generated for each 
replicate of ATAC-seq and RNA-seq by calculating genome-wide coverage of aligned 
reads using the bedtools function genomecov94. For ATAC-seq samples, this coverage 
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was calculated after shifting the reads to account for the Tn5-induced bias. The 
coverage values were then normalized using DESeq2-derived size factors and replicates 
were combined to create one signal track for each sample type. ATAC-seq and RNA-
seq coverage plots were generated using the Integrated Genomics Viewer95.  
 
Transcription factor peak assignment: Using the MEME96-curated CisBP97 
transcription factor binding motif (TFBM) reference, we scanned the mouse ATAC-seq 
peak atlas with FIMO98 to find peaks likely to contain each TFBM (P < 10-4). The 
MEME cisBP reference for direct and inferred motifs for Mus musculus was curated by 
the MEME suite developers as follows: to reduce redundancy, for each transcription 
factor a single motif was selected according to the following precedence rules: The 
direct motif was chosen if there was one, otherwise the inferred motif with the highest 
DNA binding domain (DBD) similarity (according to CisBP) to a transcription factor in 
another species with a direct motif was chosen. If there was more than one direct motif 
or inferred motif with the highest DBD similarity, a motif was chosen according to its 
provenance (CisBP ‘Motif_Type’ attribute) in the following order: ChIP-seq, 
HocoMoco, DeBoer11, PBM, SELEX, B1H, High-throughput Selex CAGE, 
PBM:CSA:DIP-chip, ChIP-chip, COMPILED, DNaseI footprinting. Each motif thus 
determined was linked to a single transcription factor in the CisBP database, following 
the same precedence rules. The final reference contained 718 motifs between 6 and 
30 bp in width (average width, 10.7 bp). Transcription factors with similar FIMO-
predicted target peaks were combined into transcription factor families. Similarity of 
predicted target peak sets was measured using the Jaccard index (size of 
intersection/size of union). Transcription factors with Jaccard indices greater than 0.7 
were combined for further analyses. Relative transcription factor accessibility was 
calculated using two one-sided Wilcoxon rank-sign tests comparing the distributions of 
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peak heights for peaks containing FIMO-predicted transcription factor binding sites. 
Peak height was defined as the maximum observed number of reads overlapping at any 
point in the defined peak region.  
 
Comparison of human and mouse ATAC-seq atlases: The UCSC liftOver tool99 was 
used to convert the mouse ATAC-seq peak atlas from mm10 coordinates to hg38 
coordinates. The converted mouse atlas was then compared to the human atlas and 
20,642 mouse peaks were within 100 bp of a human peak. We compared the results 
from the UCSC liftover tool and an alternative method, bnMapper100, and confirmed 
that the set of peaks mapped by bnMapper and by the UCSC liftOver tool was nearly 
identical (57,383 out of 75,689 by liftOver and 58,299 out of 75,689 by bnMapper). 
Additionally, all 57,223 peaks mapped to hg38 by both tools were mapped to the same 
chromosomal positions. The majority of these conserved peaks were found in promoter 
regions (56.4%), whereas relatively fewer were found in intergenic (22.4%), intronic 
(19.6%), and exonic (1.5%) regions. For non-promoter peaks conserved between human 
and mouse, Spearman correlations of log2(FC) were calculated between human N and 
human EM, CM or PD1hi TIL versus log2(FC) between mouse N and functional E5, E7, 
M and dysfunctional L5 to L60.  
 
RNA-seq: Raw RNA-seq reads were trimmed and filtered for quality using Trim 
Galore! v0.4.085, powered by CutAdapt v1.8.186 and FastQC v0.11.387. Paired-end reads 
were aligned using STAR101 against either mm10 or hg38. The RefSeq transcript 
annotations of the hg38 version of the human genome and the mm10 version of the 
mouse genome were used for the genomic location of transcription units. Reads 
aligning to annotated exon regions were counted using the summarizeOverlaps function 
of the R packages GenomicAlignments v1.2.2 and GenomicRanges v1.18.493. 
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Differential expression of genes across cell types was calculated using DESeq292 v1.6.3. 
FDR correction of 0.05 was imposed unless otherwise stated. A log2 fold change cutoff 
of 1 was used in some analyses as indicated.  
 
Pathway analysis: Enrichment of gene ontology terms in sets of ATAC-seq peaks was 
calculated using GREAT (Genomic Regions Enrichment of Annotations Tool) using 
default parameters102. The full ATAC-seq atlas was used as the background set.  
 
Membrane protein analysis: To identify membrane proteins that distinguished early 
(L5–L7) from late (L14–L60) dysfunctional TST, RNA-seq data was analyzed for genes 
contained within the gene ontology103 category 0016020 (membrane proteins). The top 
50 most up- and down-regulated genes (size-factor normalized RPKM) when compared 
between L5–L7 and L14–L60 were plotted in a heat map (row-normalized). Protein 
expression was assessed by flow cytometry for those membrane proteins for which 
monoclonal antibodies were available. Mouse targets (clone; supplier): CD5 (53-7.3; 
eBioscience), CD30L (RM153; eBioscience), CD38 (90; Biolegend), and CD101 
(Moushi101; eBioscience). Human targets: CD5 (L17F12; Biolegend), CD38 (HB7; 
eBioscience), CD101 (BB27; Biolegend)  
 
Data availability: All data generated and supporting the findings of this study are 
available within the paper. The RNA-seq and ATAC-seq data have been deposited in 
the Gene Expression Omnibus (GEO Super-Series accession number GSE89309 
(GSE89307 for RNA-seq, GSE89308 for ATAC-seq. 
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CHAPTER 4  
MODELING OF TRANSCRIPTION FACTOR ACTIVITIES TO PREDICT 
CHANGES IN GENE EXPRESSION 
 
4.1 Introduction 
 
As discussed previously, prolonged exposure of a T cell to its antigen can induce a 
dysfunctional state wherein the cell no longer produces common inhibitory molecules 
and the transcriptional state of the cell changes29. These cells are no longer able to 
induce apoptosis in their target cells. This state can be induced by both cancer, where 
the antigen is a neoantigen, or by a chronic viral infection, where the antigen is a viral 
protein.  However, although both of these antigens may induce a dysfunctional state, the 
antigens themselves arise through different mechanisms and it is not clear if these 
differences influence the initiation and progression of this dysfunctional program. 
Additionally, although the dysfunction induced by these two types of antigens appears 
similar, we do not know if these processes are the same below the surface, for example, 
at the epigenetic level. In this chapter I will describe my work attempting to address 
these questions. 
 
4.2  T cell maturation and self-tolerance mechanisms 
 
As it is critical that T cells do not activate aberrantly, there are complex central and 
peripheral mechanisms in place to ensure that mature T cells tolerate self-proteins104. 
When T cells are being developed in the thymus, they are exposed to self-proteins 
loaded into the major histocompatibility complex (MHC). T cells that are strongly 
reactive to these self-proteins are deleted through apoptosis or are modified in other 
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ways. T cells that are not reactive at all are ignored and do not continue developing. 
Only the T cells that are slightly reactive to the self-proteins are able to mature, 
ensuring that functional, but not self-reactive, T cells are produced. 
As not all self-antigens are expressed in the thymus, mechanisms of central 
tolerance are not completely effective. Additional protective mechanisms exist outside 
the thymus to block the activity of self-reactive T cells that did not encounter their self-
antigen during development.  In secondary immune organs such as the lymph nodes and 
spleen, immature dendritic cells (tolerogenic DCs) present additional self-antigens to T 
cells without a co-stimulatory signal. The lack of a stimulatory signal forces the T cell 
into a long-term inactive state, anergy. Alternatively, DCs expressing BTLA can induce 
the self-reactive T cell to differentiate to a regulatory T cell (Treg)105. 
Both cancer and chronic viral infections can induce a dysfunctional state similar 
to aenergy. What is not clear however, is how similar these states are, if their initiations 
and progressions are similar, and if the resulting dysfunction is reversible.  
 
3.3 Computational modeling of two dysfunctional T cell states 
 
In order to compare the nonfunctional states induced in tumor-specific T cells (TSTs) 
and T cells in a chronic infection environment, we compared their epigenetic and 
transcriptional states. We modeled the activities of expressed transcription factors and 
determined their relative importance during various cell state transitions. To model the 
TSTs, we used the RNA-seq and ATAC-seq data described in Chapter 3 for normal 
CD8+ cells and for the cells in the tumor environment. To model the viral infection, we 
used RNA-seq and ATAC-seq data for CD8+ T cells from the mouse model for chronic 
lymphocytic choriomeningitis virus (LCMV) infection from a study performed in the 
Wherry lab106. In this study, both RNA-seq and expression microarrays were used to 
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characterize gene expression changes. In order to minimize differences between the 
tumor and viral samples, we only used the viral samples with matching RNA-seq data 
(Table 4.1). 
  
Table 4.1: Samples used in modeling 
RNA-seq and ATAC-seq samples used in modeling for tumor and chronic viral 
infection environments 
 
 Tumor Viral 
Naïve X X 
Effector X  
Memory X  
Dysfunctional / Exhausted X X 
 
  
A unified atlas for LCMV and TST cells was generated in order to minimize 
experiment and cell-type specific differences in chromatin accessibility across the 
samples. This atlas was created by first calling reproducible peaks for each cell type and 
experiment separately and then combining the peaks across experiments. The 
accessibility measures for the peaks were then batch-corrected by training a generalized 
linear model (GLM) on the data and including the batch as a confounding factor. The 
portion of the accessibility value that could be attributed to the batch could then be 
subtracted out, leaving values that could more accurately be compared across 
experiments. Figure 4.1 shows a PCA of the combined data and it appears from this 
analysis that the normal naïve and effector cells are similar across experiments while 
the dysfunctional and exhausted cell types are also similar although their environments 
differ. 
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Similar to the work described in the previous chapter, we used cisBP’s defined 
sequence binding motifs96 for transcription factors expressed in the relevant RNA-seq 
data to define potential transcription factor binding events within regions of accessible 
chromatin genome-wide. Genes were defined as “potentially-regulated” by a 
transcription factor if there was a cisBP-defined binding site for that TF within one or 
more chromatin accessibility peaks assigned to that gene. As the location of an 
accessible region of chromatin relative to a protein-coding gene is known to impact the 
type of regulation, atlas peaks were split into four groups for modeling purposes: 
“promoter peaks”, “opening peaks”, “closing peaks”, and “stable peaks”.  Peaks were 
split based on their change in accessibility in the cell type transition being modeled, 
leading to the opening, closing, and stable groups. Promoter peaks were separated into 
Figure 4.1: PCA of CD8+ T cell types.  
First two components from a principal component analysis using the accessibility 
values of the top 10,000 most accessible peaks in any cell type after batch 
correction, comparing normal CD8+ T cells with T cells in LCMV and tumor 
environments  
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their own group since they are often constitutively accessible. Using this framework, a 
gene-by-TF matrix was created and used as input to a generalized linear model. The 
goal of this model was to predict gene expression change from ATAC-seq and TF 
binding data in order to learn the relative importance of each expressed TF in 
orchestrating that change. 
This modeling approach was able to capture changes in RNA expression to 
varying degrees, depending on the cell type transition being modeled (Figure 4.2). The 
transition from dysfunctional day 7 to day 14 was one of the more accurately predicted 
transitions (Spearman correlation = 0.592, N=1076) whereas expression changes 
occurring during cell transitions with fewer chromatin changes, such as effector to 
memory cells, were not captured as well (Spearman correlation = 0.319, N=373). 
Across all transitions, genes with more reproducible open chromatin regions in any cell 
type (potentially more tightly regulated genes) were predicted more accurately (Table 
4.2).    
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Figure 4.2: Model performance scatterplots. 
Scatterplots depicting measured RNA log2 fold change vs predicted RNA log2 
fold change for various cell type transitions  
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Table 4.2: Model performance across six cell type transitions 
Spearman (rank) correlations of measured vs predicted RNA fold change in six cell type 
transitions. First column: Correlation calculated using all differentially expressed genes. 
Second column: Correlation calculated using only high-complexity differentially 
expressed genes (genes with 7 or more assigned peaks).  
 
 
  
 
 
 
 
Next, we looked at the learned weights from the model to determine the relative 
importance of each transcription factor in the prediction of gene expression changes. By 
multiplying the learned TF weight vector (W) by the binding scores derived from cisBP 
and the ATAC-seq data, we are able to determine which TFs are best able to explain 
changes in gene expression for each cell type transition. As a positive control, we were 
able to recover several TFs known to be critical in T cell activation from naïve to 
effector states: Bach1, Eomes, Nfat family transcription factors, and Tbx21 (Tbet). We 
also found that closing of Lef1/Tcf family binding sites explained the lower expression 
of Naïve-specific genes in effector cells (Figure 4.3 (left), Table 4.3).  
 In contrast to normal T cell activation, Klf family proteins seemed to play a 
stronger role in the transitions from naïve to tumor-specific dysfunction and to LCMV-
induced exhaustion. Both of these transitions showed many members of the Klf family 
explaining gene expression changes in both the positive and negative directions. 
Additionally, neither of the dysfunctional transitions showed Tbx21 (Tbet) to be a 
Cell type transition 
Spearman corr.  
(all genes) 
Spearman corr.  
(high-complexity genes) 
N to E5 0.534 0.610 
E7 to M 0.319 0.430 
N to L5 0.511 0.569 
N to L14 0.630 0.630 
L7 to L14 0.592 0.639 
N to Exhausted (LCMV) 0.615 0.647 
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major influencer.  The activation of Nfat family members also appeared to be muted in 
the transition to LCMV-induced exhaustion, in contrast to the hyper-activation of Nfat 
in the tumor-specific dysfunction transition. More analysis and experimental follow-up 
is needed to confirm these findings. 
  Based on this analysis, it appears that although the chromatin landscapes of 
tumor-specific dysfunctional T cells and LCMV-induced exhausted T cells appear 
similar (Figure 4.1), there are differences in the underlying regulatory mechanisms 
controlling the cell state changes (Figure 4.3). 
 
 
 
Table 4.3: Influential transcription factors identified by model 
Summary of Figure 4.3 depicting learned weights for each transcription factor weighted 
by the binding score derived from cisBP. Here are shown transcription factors that 
explain up- or down- regulation of genes in each of the three cell type transitions 
analyzed. 
 
 
Up-regulation Down-regulation 
Naïve to E5 Bach1, Batf, Eomes, Fos/Jun, 
Klf, Nfat, Nfkb2, Pbx2, Runx1/3, 
Smarcc1, Tbx21, Trp53 
Klf, Lef1/Tcf, Pbx2, Trp53 
Naïve to L5 Bach1, Eomes, Fosb, Klf, Nfatc1, 
Nfkb1, Klf, Pbx2 
Bach2, Klf6, Nfkb1/2, 
Pbx2, Tcf, Trp53 
Naïve to 
Exhausted 
Bach1, Eomes, Fos, Fox, Klf, 
Lef1, Nfatc2, Prdm1 
Klf, Lef1, Sox4, Tcf, 
Trp53 
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 Figure 4.3: Heatmaps of learned transcription factor weights scaled by 
cisBP-derived binding terms. 
Each heatmap depicts the relative importance of each transcription factor in the 
up- or down-regulation of genes during cell type transitions. (left) Naïve to 
effector day 5 (E5) (center) Naïve to tumor-associated dysfunction day 5 (L5) 
(right) Naïve to LCMV-induced exhaustion. Columns represent up-regulated 
(orange) or down-regulated (blue) genes in each cell type transition. Rows 
represent transcription factor binding sites that open (orange) or close (blue) in 
each transition. Rows are additionally annotated as either promoter sites (pink) or 
enhancer sites (teal). Red indicates that the transcription factor contributed 
positively to gene expression (up-regulation) and blue indicates the opposite 
(down-regulation). Selected transcription factors are highlighted to the right of 
each heatmap.  
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CHAPTER 5  
CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 Discussion 
 
The question of gene regulation is a complex and varied one. In this work I describe 
two studies that investigate different angles of gene regulation. In chapter 2 I describe 
SplashRNA, a cascaded SVM classifier trained to predict potent shRNA reagents. In 
chapter 3 I present an in-depth analysis of chromatin accessibility in CD8+ T cells and 
how this accessibility changes and potentially regulates cell state changes.  An 
extension of this analysis was presented in chapter 4, in which the relationship between 
accessible chromatin, predicted transcription factor binding sites, and the resulting 
changes in gene expression were modeled using a generalized linear model.  
 
5.2  shRNA potency prediction 
 
SplashRNA was developed to more accurately predict potent shRNA molecules using 
only sequence information. It is comprised of a linear combination of two SVM 
classifiers, one trained on extensive miR-30 shRNA backbone data, and the second 
trained on a smaller amount of the newer miR-E backbone data. This combination 
allowed the classifier to learn basic rules of shRNA potency from the larger but slightly 
out-of-date miR-30 data and then alter those rules using the sparse but newer miR-E 
data. This combination led to unprecedented prediction performance in novel prediction 
tasks relative to existing methods (shRNA with a SplashRNA score >1 have an 80% 
probability of strong knockdown and over 80% of human and mouse genes have at least 
5 predicted shRNAs with scores of 1 or greater). The SplashRNA project also included 
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an extensive curation of the transcribed sequences in human and mouse genomes in 
order to target the relevant transcript space in both species. Only sequences transcribed 
in all RNA isoforms of a gene were used as input and poly-adenylation libraries were 
used to determine the most proximal 3` polyadenylation site for each gene in order to 
prevent targeting a gene after this cleavage event. These features were incorporated 
with the SplashRNA algorithm into an open-source online tool that can be found at 
splashrna.mskcc.org. A docker instance of the algorithm is also available for download 
(https://hub.docker.com/r/lfairchild/splashrna-docker/).  
Though this approach of cascading classifiers was developed for face detection 
by sequentially detecting potential face components and exiting calculation early if no 
components are found, we applied the concept here for shRNA prediction. This method 
of cascading SVM classifiers could easily be extended to newer biological 
developments such as CRISPR/cas9 reagent prediction. Although there is currently not 
a large pool of CRISPR training data and the specific targeting rules to vary from those 
used in shRNA/siRNA, the overall problem is similar. More broadly, any situation with 
a shift in the target prediction (e.g. miR-30 to miR-E prediction) may benefit from this 
type of approach, as the cascade allows for the classification rules to be refined at each 
step. 
Additionally, although a strength of this classifier lies in its ability to predict 
shRNA potency using only sequence features, in some circumstances it may be 
advantageous to add other non-sequence features to the model, potentially increasing 
performance. Potential non-sequence features would include RNA structure prediction 
to locate regions of the target mRNA that could potentially be bound, RNA 
modifications including methylation which could conceivably affect shRNA/RISC 
interaction with the target mRNA, and thermodynamic stability of the shRNA/mRNA 
complex. 
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Innovations in shRNA technology continue to push the boundary of what is 
possible with shRNA. Constructs are in development that can deliver several shRNA at 
once, allowing for the knock down of multiple genes simultaneously. Since multiple 
shRNA molecules are being delivered, a heavier burden is being placed on the cell’s 
machinery. Early experiments suggest that SplashRNA predictions continue to perform 
well in this setting, but some optimization may improve performance. 
 
5.3 T cell epigenetic modeling 
 
Although the immune system and CD8+ T cells have been studied extensively, it is still 
not clear what causes them to become inappropriately nonfunctional, for example in the 
presence of tumor cells. In chapter 3 we addressed this question by molecularly 
profiling CD8+ T cells in acute infection and malignant tumor environments using both 
ATAC-seq and RNA-seq. This in-depth sequence information allowed us to 
characterize the T cells to an extent not previously possible and to determine chromatin 
states corresponding to normal and dysfunctional T cell states. Using RNA-seq data, we 
were able to identify cell-surface markers that could reliably differentiate between TSTs 
extracted from the premalignant environment that could be functionally rescued from 
those that were in a fixed dysfunctional state. This type of testing could potentially be 
adapted to patients to determine whether they are candidates for checkpoint blockade 
therapy; meaning that their T cells could potentially be reinvigorated by an anti-PD1 or 
anti-CTLA4 antibody.  
 In addition to determining cell-surface markers that differentiate TSTs, we 
analyzed the accessibility of predicted transcription factor binding sites to determine 
which transcription factors were most likely involved in the transitions from naïve to 
early dysfunctional cells and from early (plastic) dysfunction to late (fixed) dysfunction. 
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This analysis revealed that NFAT family member binding sites became significantly 
more accessible in early dysfunctional cells relative to their naïve predecessors, and that 
binding sites for TCF family members (including LEF1) closed during the transition 
from early to late dysfunction, correlating with the decline in TCF1 protein levels. 
Furthermore, we were able to validate the roles of these two predicted transcription 
factor families in the progression to T cell dysfunction using an in vivo pharmacologic 
strategy. Pharmacologically down-regulating NFAT activity and activating the 
WNT/TCF1 pathway led to significantly more cells remaining reprogrammable relative 
to controls after being exposed to the dysfunction-inducing environment, indicating that 
these transcription factor families play a role in regulating this transition to dysfunction. 
 Although we did identify transcription factors that play a role in the progression 
to dysfunction and we were able to slow the progression to dysfunction by targeting 
these TF families, we do not know if the result we observed was only at the level of 
phenotype (restoration of effector cytokines) or if the treatment also slowed the 
chromatin remodeling to the dysfunctional signature. This would give an indication as 
to whether the drug treatment was able to fully protect some cells from progressing to 
dysfunction, or if it was only delaying this progression.  
 Another question that remains unanswered is whether the transcription factors 
are acting primarily through a relatively small set of “key” genes, or if their effect is 
truly global. In the case where transcription factors are modulating a small number of 
genes, the binding sites for these transcription factors could be individually modulated 
using CRISPR, as was done for a potential PD1-regulating site in Sen & Kaminski et al. 
(2016) 73, in order to determine the precise effect of each transcription factor. More 
likely however, is that the effects of these transcription factors form a complicated 
genome-wide network of signals that would be impossible to elucidate experimentally.  
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 In chapter 4, I attempted to take this type of transcription factor binding analysis 
one step farther by directly modeling the impact of each expressed transcription factor 
on gene expression during a cell type transition. By doing this, I attempted to determine 
the relative importance of each transcription factor in orchestrating that cell type 
transition. This type of analysis more directly addresses the molecular underpinnings of 
these cell state changes and may point toward potential treatment paths that have not 
been explored. Although a model for each cell state change is technically true, having 
one model that could explain all the cell type changes, for example by learning in a 
multitask setting, would be a cleaner solution. This strategy could learn a universal 
transcription factor weighting and then a task (or cell type transition) specific weighting 
that would modify the transcription factor importance weights for each individual cell 
type transition. Additionally, allowing the model to learn from all cell type transitions 
would likely increase performance as the training data would be increased.  
 The method used to match transcription factors to target genes, using predicted 
binding scores derived from cisBP, can likely be improved upon to increase overall 
model performance. It is not feasible to collect in vivo binding data for all transcription 
factors in the cell type of interest, but perhaps creating an atlas of binding sites for 
transcription factors profiled in the ENCODE project (encyclopedia of DNA 
elements)107 in any cell type would provide a more realistic view of the landscape of 
binding events for some transcription factors.  
An additional challenge is mapping regions of accessible chromatin genes they 
are regulating. Currently, we map each chromatin element to its nearest gene but this 
assumes that regulatory elements are always closely positioned to their target genes. 
Having DNA looping information such as Hi-C or Hi-ChIP data would be valuable in 
determining topologically associating domains (TADs), or regions that are likely to be 
co-regulated. However, since this data would be difficult to generate in many rare cell 
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populations, it may be more feasible to reassign peaks associated with high-error genes, 
as proposed in Gonzalez & Setty et al (2015)108. 
 
5.4 Conclusion 
 
The two studies included in this document describe forays into different realms of 
biology, but at their hearts they are both questions of gene regulation that are being 
answered predominantly in a computational manner. In chapter 2 I described 
SplashRNA, a machine learning method to predict potent shRNAs from sequence alone. 
This method allows for higher efficiency in the targeted knockdown of RNA transcripts 
in the lab – a critical tool in the study of gene regulation. In chapter 3 I described a 
computational analysis of chromatin accessibility and gene expression data in tumor-
specific T cells. This study seeks to uncover the principles guiding gene regulation in 
this setting and would have been impossible without computational investigation. 
Together, these two studies show the breadth and importance of computational analysis 
and innovation in the biological sciences. 
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